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Abstract 
The objectives of this study were to: 1) show non-inferiority of home-fortification 
with a daily dose of 3mg iron as NaFeEDTA compared with 12.5 mg iron as 
encapsulated ferrous fumarate. 2)  Assess to what extent adherence measured by 
sachet count or self-reporting forms agrees with adherence measured by MEMS 
electronic device. 3) Assess the diagnostic performance of zinc protoporphyrin either 
alone or combined with haemoglobin concentration in children. 
 
Methods: We gave chemoprevention by dihydroartemisinin-piperaquine, 
albendazole and praziquantel to 338 afebrile children with haemoglobin 
concentration ≥70 g/L. We randomly allocated them to daily home-fortification for 30 
days with either placebo, 3mg iron as NaFeEDTA, or 12.5 mg iron as encapsulated 
ferrous fumarate. Each child received 30 sachets of micronutrient powders in a 
MEMS device, a self-reporting form and requested to store empty sachets. At 
baseline and after 30 days of intervention, haemoglobin concentration, plasma iron 
markers, plasma inflammation markers, Plasmodium infection in blood samples and 
adherence to home-fortification were assessed.  
 
Results: Home-fortification with either of the iron interventions did not improved 
haemoglobin concentration, plasma ferritin concentration and plasma transferrin 
receptor concentration. Both self-reporting and sachet counts confirmed over-
estimation in adherence measurements when compared to MEMS device. Addition 
of whole blood ZPP or erythrocyte ZPP to haemoglobin concentration increased the 
area-under-the-ROC-curve. 
  
Conclusions: Daily home-fortification with either 3 mg iron as NaFeEDTA or 12.5 
mg iron as encapsulated ferrous fumarate was not efficacious. This failure precluded 
further assessment of the non-inferiority of 3 mg iron as NaFeEDTA compared to 
12.5 mg iron as encapsulated ferrous fumarate. Self-reporting and sachet counts are 
less accurate in measuring daily home-fortification with micronutrient powders 
compared to the MEMS device. In children, whole blood ZPP and erythrocyte ZPP 
combined with haemoglobin concentration have added diagnostic value in detecting 
iron deficiency compared to haemoglobin concentration alone.  
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Preface 
 
This thesis has been compiled to address research gaps that are of public health 
concern. No study has so far compared the efficacy of daily home fortification with 
12.5 mg iron as ferrous fumarate versus 3mg iron as NaFeEDTA. Information 
regarding accuracy in measuring adherence to home fortification powders by self-
reporting and sachet counts outside a gold standard is wanting. The following 
chapters outline procedures, findings and conclusions; 
  
Chapter 1: Provides background information on home-fortification with iron, issues 
guiding the rationale of the study, study population and study area profile, problem 
statement, conceptual framework, objectives and description of study endpoints and 
procedures for ethical approval.  
 
Chapter 2: Details the study protocol, including the design and its rationale, sample 
size determination and procedures for participants’ recruitment, randomization, 
blinding, interventions, statistical analysis and data safety monitoring. The 
discussion section presents arguments for and against the use of placebos and use of 
multiplicity in a non-inferiority study.   Published by Contemporary Clinical Trials )  
 
Chapter 3: This research paper covers the main aim of this study and examines the 
efficacy of 3mg iron as NaFeEDTA and12.5 mg iron as encapsulated ferrous 
fumarate in young children protected against malaria by chemoprevention. Methods 
and statistical analysis to achieve this objective are detailed. The paper also provides 
results of a meta-analysis showing the effect of iron treatment on haemoglobin 
concentration. Greater focus is on the discussion section that explains possible 
reasons for lack of efficacy.   Published by BMC-Medicine)  
 
Chapter 4: This research paper examines the accuracy of measuring adherence to 
daily home fortification of micronutrient powders using self-reporting forms and 
sachet count method and gives reasons why self-reporting forms and sachet count 
methods should not be used alone but alongside a gold standard method (MEMS 
electronic device) when assessing adherence to daily home-fortification in children 
(Submitted for publication) 
 
Chapter 5: Provides information about factors associated with zinc protoporphyrin 
(ZPP) in children aged 1-3 years and also examines  the diagnostic performance and 
utility of ZPP, either alone or in combination with haemoglobin, in the identification 
of iron deficiency ( submitted for publication). 
 
Chapter 6: A summary of discussions and public health implications, study 
limitations and recommendations for further research are presented here. 
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Chapter 1: General introduction  
 
1.1 Background of iron fortification powders 
 
Iron fortification is one of the recommended iron intervention strategies aimed at 
providing additional iron to vulnerable target groups in an appropriate amount 
regardless of how much food they consume for improving their iron status. Other 
iron interventions may be administered as either a) iron supplementation pills, 
syrups, iron drops or capsules which supply an optimal amount of iron in a highly 
absorbable form and have been suggested to be a fast way to control iron 
deficiencies [1] or b) iron added to staple foods, infant formulas, sauces and other 
condiments during processing [2]. 
 
In 1995, the United States Agency for International Development (USAID) and the 
Institute of Child Health held a meeting in London having recognised that children 
6-24 months old who are most at risk of iron deficiency had difficulties in 
swallowing prescribed iron supplemental tablets [3]. In addition, lack of low-cost 
generic prophylactic iron supplements suitable for them compelled UNICEF in 
collaboration with World Health Organisation (WHO), USAID, pharmaceutical 
industry and international experts to convene a consultation meeting in 1996 with 
the goal of identifying the most appropriate formulation and regimen suitable for 
this age category of children [3]. They also looked at the possibility of including 
other micronutrients that can easily be combined with iron in the formulation. The 
meeting concluded that coated or microencapsulated iron with other vitamins and 
minerals sprinkled on the child’s semi-solid, ready prepared foods was the most 
appropriate solution [3]. A formulation comprising of 15 micronutrients, including 
iron has been evaluated and is currently in use (http://www.hftag.org/). To meet 
specific micronutrient needs for iron deficient children, WHO recommended 
universal home fortification with 12.5mg iron as ferrous fumarate for children aged 
6-23 months in populations where the prevalence of anaemia in children under 5 
years of age is ≥20% alongside the control of malaria in malaria-endemic areas [4]. 
The formulation also contains vitamin A and zinc whose deficiencies develop 
concurrently with iron deficiency. Follow-up trials examining therapeutic effects of 
the WHO formulation resulted in rapid reduction of iron deficiencies and anaemia in 
infants and young children [4] and were more cost-effective when compared to 
electrolyte iron supplementation [5]. 
 
1.2 Anaemia in pre-school children: the global perspective 
 
Iron deficiency is a public health problem and the most common nutrition deficiency 
all over the world [6-8]. It also has a direct consequent effect on anaemia [9]. Other 
risk factors for anaemia include micronutrient deficiencies (folate, copper, zinc, 
vitamin A and vitamin B12), infections (malaria, intestinal parasites, schistosomiasis, 
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human immunodeficiency virus and inherited blood disorders (e.g., sickle cell, a-
thalassemia) [10]. Globally, WHO estimates that slightly fewer than fifty per cent of 
pre-school children are anaemic [11] but Africa has the highest prevalence (64%) of 
anaemic pre-school children [12], compared to Asia, Latin America and four times 
higher than Europe (Figure 1). In sub-Saharan Africa, paediatric anaemia is a major 
public health problem especially in malaria endemic areas; hospital based statistics 
show that up to 75% of children are estimated to be anaemic mainly due to malaria 
and iron deficiency [13]. 
 
 
 
 
Figure 1: Global prevalence of anaemia in preschool children 1993-2005 
(Adapted from: WHO/CDC, 2008).  
 
1.3 Effect of iron interventions on infections and anaemia 
 
Iron interventions are essential for reducing iron deficiency and enhancing growth 
and cognitive development in children. Trials have shown, however, that 
supplemental iron plays a major role in proliferation of bacteria, malaria parasites 
and most pathogenic micro-organisms in the body [14,15]. In sub-Saharan Africa, the 
most common parasitic infections among young children are malaria, 
schistosomiasis and soil-transmitted helminthic infections. Randomised trials in 
young children in Africa and Asia showed that home fortification with the 
recommended dose of 12.5mg iron as ferrous fumarate, although shown to reduce 
iron deficiency, led to an excess burden of diarrhoea, and increased numbers of 
potentially pathogenic enterobacteria, with a concurrent increase in gut 
inflammation [14-16]. Also, there is substantial evidence that iron interventions in 
young children can also increase proliferation of P. falciparum [4], which has been 
associated with haemolysis and dyserythropoiesis. This can be explained by: a) an 
increase in the destruction of the red cells; b) a high level of parasitaemia rosetting 
(clumping together of uninfected cells around infected cells); c) cyto-adherence; and 
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d) increased clearance of both infected and uninfected erythrocytes [17] which 
explains the fall of haemoglobin levels during and following an episode of malaria 
[11].. Infections can result in a) retention of intracellular iron; b) decreased blood 
transport of iron because of reduced transferrin; and c) elevated hepcidin production 
by hepatocytes, which may inhibit iron absorption needed for erythropoiesis, thus 
making less iron available for haemoglobin formation. This reduction of iron 
absorption through infection -induced inflammation has been shown in a study 
conducted among 18-36 months old Gambian children that showed significant 
inhibition of oral iron in children with malarial infection when compared with those 
with iron deficiency anaemia but a reverse of iron absorption was noted two weeks 
after treatment of malaria infection [18] .  
 
Among WHO regions, sub-Saharan Africa carries the largest disease burden caused 
by co-existence of P. falciparum and helminth species (roundworms, Ascaris 
lumbricoides; hookworms, Ancyclostoma duodenale and Necator americanus; and 
whipworms, Trichuris trichiuria) [19]. Their growth and development is influenced 
by environmental factors such as favourable climate that determines survival of 
mosquitoes and free-living stages of helminths [20]. Resource-poor communities 
where the prevalence of soil-transmitted helminths exceeds 20%, such as the shores 
of Lake Victoria in Kenya [21], are apparently the same areas where the prevalence 
of P. falciparum infection is high, estimated at ~44% [22]. Co-infection of P. falciparum 
and soil-transmitted helminths increases the risk of low haemoglobin concentrations 
and a high prevalence of anaemia among pre-school and school children [23]. Also, 
the risk of developing falciparum malaria has been shown to be more specifically 
linked to increased number of helminths in the body [24].  
 
Furthermore, co-infection of malaria parasites with bacteria can aggravate the 
severity of anaemia. For example, a trial conducted in Thailand among 169 patients 
with cerebral malaria showed that 94% of cases were anaemic (haematocrit <35%) 
and the severity of anaemia was worse among patients with bacterial infections [25]. 
In this trial and as recommended by WHO we took measures to control these 
infections among the study participants prior iron interventions.  
 
1.4 Issues guiding rationale for study design  
 
1.4.1 Pharmanutrient approaches in integrated iron intervention strategies 
Iron fortification of industrially produced foods is feasible, but has limited impact in 
rural areas, where farmer families rely on subsistence farming. Bio-fortification 
entails the breeding of staple crops with high levels of micronutrients in their edible 
parts, but it remains to be proven if this can effectively raise the supply of 
bioavailable iron in African conditions. Dietary modification comprises soaking, 
germination and other measures to reduce the content of iron absorption inhibitors 
that occur naturally in cereals [26]. Whilst these interventions are useful, they have 
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limited efficacy, require behaviour change and are difficult to scale up in public 
health programmes. Thus pharmanutrient interventions remain an essential element 
in the control of iron deficiency anaemia of young children. Home fortification of 
foods with powders containing micronutrients are currently recommended as a 
method to increase the intake of vitamins and minerals in children, alternatively or 
complementary to other interventions such as oral iron supplementation. 
 
1.4.2 Formulation and dosage of iron in home fortificants 
Based on evidence that iron interventions increase the risk of malaria, bacterial and 
other parasitic infections [14-16,18,27], the dose of iron that is most commonly used 
(12.5 mg as ferrous salts) has been argued to be relatively high when administered in 
a single meal for children 6-23 months [28]. To solve this problem, it has been 
suggested to use home-fortification with reduced amounts of highly bioavailable 
iron (3 mg iron as NaFeEDTA) [29]. This is because in an acid condition such as in 
the stomach the EDTA moiety that chelates iron results in better iron absorption than 
iron as ferrous salts. A study conducted in Kenya showed that iron as NaFeEDTA is 
highly efficacious and an attractive choice even in areas with high phytate diet. 
Children with iron deficiency and anaemia benefitted more from iron fortification 
with NaFeEDTA when compared to placebo or fortification with electrolytic iron 
[30]. EDTA causes minimal organoleptic problems [31] and has the ability to 
deactivate food spoilage enzymes that would otherwise cause food products to 
become rancid, lose colour or flavour [32]. EDTA is less affected by inhibitors of iron 
absorption [33] and can be added to a variety of iron vehicles such as wheat cereal, 
maize flour and fish sauce in children, however, the daily dose of iron as NaFeEDTA 
should not exceed 3 mg to remain within the acceptable daily intake of EDTA (0-1.9 
mg kg-1 day-1) [34]. 
 
Reducing the iron dose may decrease the amount of luminal iron and thus prevent a 
shift towards increased risk of iron-induced malaria and a more pathogenic profile 
in intestinal biota composition as reported with oral iron supplementation 
interventions [35-36]. Also, it may result in fewer adverse effects, improved 
adherence and improved effectiveness. Thus, home fortification with a high dose of 
iron (12.5 mg) as ferrous fumarate iron or a low dose (3 mg) as NaFeEDTA may 
result in similar or even higher doses of absorbed iron, but the risks of acquiring the 
adverse events associated with such systemic diseases are likely to depend on the 
absorbed amount of iron hence the safety of this approach can potentially be 
maintained if adequate parasitic and bacterial control measures are put in place 
during iron intervention [4, 37]. 
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1.4.3 Home fortification with iron and selected micronutrients 
About 15 micronutrients have been recommended by the Home Fortification 
Technical Advisory Group, 
(http://www.gainhealth.org/hftag/products/micronutrient-powders-mnp). By 
contrast, and based on a systematic review, WHO recently recommended that 
multiple micronutrient powders for home fortification for younger children 6-23 
months should include iron, vitamin A and zinc, and may contain other vitamins 
and minerals as need arises. For iron, WHO recommended a dose of 12.5 mg, 
preferably as encapsulated ferrous fumarate [4]. Since there is limited evidence that 
additional micronutrients to those recommended by WHO for anaemia treatment 
may bring health benefits to children in developing countries [38], it is important 
that home fortificants contain vitamins and minerals with demonstrated health 
benefits and low likelihood of harmful effects. Inclusion of vitamin A and zinc is 
well justified in view of strong evidence that supplementation with these 
micronutrients results in marked reductions in child mortality or morbidity [39, 
40]  although recent evidence is questioning whether vitamin A remains efficacious 
against altered levels of vitamin A nutritive in recent years. In addition, there is no 
evidence that zinc adversely affects malaria rates in African children [41], whereas 
vitamin A, given alone or in combination with zinc, may reduce malaria rates [42,43] 
 
The inclusion of folic acid is controversial. Folate deficiency is not a public health 
problem among children in developing countries [44] and convincing evidence that 
folate deficiency is common in children in malaria-endemic areas is lacking. Also, 
folic acid supplementation has not been shown to have a beneficial effect on anaemia 
[45]. Furthermore, Kenyan children are no longer treated with antifolate antimalarial 
drugs (sulfadoxine-pyrimethamine. Thus in the studies described in this thesis, we 
excluded folic acid in the home fortification powder because of concerns that it may 
cause failure of other anti-folate drugs (e.g. contrimoxazole) [46] . Table 1 presents 
the content of the 13 micronutrients contained in 1g sachet selected for this study 
compared to that which is recommended by Ministry of Health (Kenya) and Home 
Fortification Technical Advisory Group (HF-TAG). In our study we aligned the 
content of vitamin A, iron and zinc to suit the WHO recommendation but omitted 
folic acid for reasons mentioned above. But the rest of the micronutrients are the 
same with Ministry of Health and HF-TAG. We included 3mg iron as NaFeEDTA 
because these were our experimental iron and a placebo group that had all other 
micronutrients except iron. The placebo group was necessary to prove efficacy of 
3mg iron as NaFeEDTA and to prove assay sensitivity of 12.5mg iron as 
encapsulated ferrous fumarate (details in Chapter 2). 
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Table 1: Comparisons of formulations for micronutrient powders 
*Nutrient content in this study varied from Ministry of Health (MOH) and Home-
Fortification Technical Advisory Group (HF-TAG) 
 
 
1.4.4 Measuring adherence for home fortification powders 
Better health outcomes are seen in patients who adhere to treatment than poorly 
adherent patients, even when that treatment is a placebo [47]. Treatment outcomes 
may depend on drugs and other nonspecific therapeutic effects [48]. Whereas 
researchers are interested in better outcomes, study participants are more interested 
in the impact of treatment on quality of life [49,50] because acceptance of any 
treatment strategy is a combination of true characteristics of a drug (efficacy, half-life 
and side effects) [51] and the consumer’s perceived characteristics such as product 
presentation including taste, colour, odour and texture. Good adherence to 
treatment has been associated with better health outcome and so patients’ non-
adherence may impact negatively on the society by aggravating disease and 
increasing health care costs borne by the community, thus the participants’ overall 
best interest and primary goal must be considered during adherence measurement 
[52]. However, adherence reporting for home fortification with micronutrients has 
been poor [53] because data obtained is either over-estimated masking the 
Micronutrient Study 
content 
MOH 
content 
HF-TAG 
Vitamin A μg RE* 300 400 400 
Vitamin D μg 5 5 5 
Vitamin E mg 5 5 5 
Vitamin C mg 30 30 30 
Thiamin (vitamin B1) mg 0.5 0.5 0.5 
Riboflavin (vitamin B2) mg 0.5 0.5 0.5 
Niacin (vitamin B3) 6.0 6.0 6.0 
Vitamin B6 (pyridoxine) mg 0.5 0.5 0.5 
Vitamin B12 (cobalamine) μg 0.9 0.9 0.9 
Folate μg* 0 150 Folic acid 
90mcg 
Iron 
EITHER iron as encapsulated ferrous 
fumarate, mg* 
12.5 11.0 10.0 
OR iron as NaFeEDTA, mg* 3 0 0 
OR no iron (placebo) 0 0 0 
Zinc mg* 5 4.1 4.1 
Copper mg 0.56 0.56 0.56 
Selenium μg 17 17 17 
Iodine μg 90 90 90 
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suboptimal adherence level of treatment or under-reported causing it to be 
misinterpreted as low adherence to treatment. Most commonly used measurement 
tools for adherence in most trials are self-reporting or empty sachet counts 
(synonymous with pill counts) [54]. In this trial we considered the following factors 
to enhance adherence to treatment: a) participant’s right to determine whether or not 
to accept treatment (adherence autonomy); b) researcher’s responsibility to do no 
harm (non-maleficence); c) researchers not to divulge participant’s personal 
information (privacy)[52]; d) use of a reliable tool for measuring adherence, the 
Medication Events Monitoring Systems (MEMS) which is considered a gold 
standard [55,56] was compared to self-reporting and sachet count to determine their 
accuracy. 
 
 
1.4.5 Pre-medication for the control of malaria and helminths in children  
Effective malaria control can be achieved using chemoprophylaxis [57] but this is not 
recommended for endemic areas, mostly because it can lead to loss of acquired 
immunity or delay its acquisition, resulting in increased malaria rates when the 
intervention is stopped [58]. The intermittent administration of full treatment courses 
of antimalarial medicines regardless of the presence or absence of infection aims to 
prevent malarial illness and it has been shown to substantially reduce malaria rates 
both in infants and older preschool children, without an evident rebound effect [59]. 
The protection offered by intermittent preventive treatment is mainly through a 
post-treatment prophylactic effect [60]. Among the four anti-malarial drugs 
recommended by WHO artemisinin-based combination therapy, 
dihydroartemisinin-piperaquine has been shown to be safe, well tolerated, have a 
long half-life (~30 days) and be highly effective [61-64] and it was the preferred 
choice of antimalarial drug for this trial. 
 
In resource-poor communities where the prevalence of soil-transmitted helminths is 
greater than 20%, WHO recommends mass treatment for soil transmitted helminths 
for all persons including school-age children [65]. The inclusion of pre-school 
children in mass treatment has recently been considered because of increasing 
evidence that they are equally susceptible to helminthic infections in areas of high 
soil-transmitted helminth endemicity. Recently, these preventive treatments have 
been included in routine health programs such as the expanded program for 
immunizations [66]. Administering safe, efficacious and low-cost anti-helminthics, 
like praziquantel for schistosomiasis and benzimidazole derivates (albendazole and 
mebendazole) against soil-transmitted helminthiasis has been recommended by 
WHO [67]. Of the two benzimidazole antihelmintics, albendazole has been shown to 
be effective and to have the fewest side effects in children [68]; it reduces worm 
burden by >80% [65]. A trial conducted in the Philippines among children and adults 
showed that in areas of co-endemicity, praziquantel treatment had a benefit of 
reducing hookworm infection and subsequently anaemia [69]. Also, another study 
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showed that infected children administered with anti-helminthic drugs before anti-
malarial prophylaxis had improved immunological response [70]. In this study we 
prioritised iron deficiency and anaemia related to malaria infection, taking into 
consideration other possible causes like schistosomiasis and soil transmitted 
helminths that will have to be addressed through mass treatment prior the iron 
fortification intervention. 
 
1.4.6 Selection of study site 
This study was conducted in Kisumu County located in western region of Kenya. In 
2009, UNICEF’s situation analysis report for Kenya indicated that, among pre-
schoolers, parasitaemia is common: nearly 50% and 30% of children in western 
region and coastal regions respectively have Plasmodium infections. In addition, 
infections such as diarrhoea, family size and a mother’s iron deficiency status were 
associated with a two-fold increase in childhood anaemia [71]. The situation analysis 
report further showed that spleen enlargement, mainly attributed to malaria, and 
was associated with a five-fold increase in the risk of childhood anaemia, while 
hookworm and Schistosoma infections were associated with a two-fold increase in 
risk of anaemia among mothers and men respectively.  
 
Kisumu County profile 
Kisumu county is located in Western Kenya and borders Lake Victoria, the largest 
lake in Africa and third largest in the world. The County has three districts: Kisumu 
East, Kisumu West and Nyando. The county records a population of 968,909 with a 
population density of 465 persons per sq km [72]. 
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Figure 2: Map of study location 
The population is predominately of a young generation with a larger proportion of 
the population at 30 years and below. This youthful population has led to high 
dependency ratio of ~1:1.2 and subsequently puts pressure on the available 
education, health and other social amenities [66]. The annual growth rate of the 
county is estimated at 2.8% [73] and 48% of the urban population live within the 
absolute poverty bracket nearly double the national average estimated at 29% [74]. 
The main causes of poverty include poor environmental conditions, low economy 
mostly due to unskilled workforce as most skilled workforce migrate to work in 
other major cities, low utilization of natural resources and socio-cultural factors. A 
high poverty rate in the district has contributed towards high school drop outs 
among the primary school population where more than 50% of the children cannot 
continue with their secondary school education [67]. Low education level has been 
associated with poor maternal and child health care practices among the Luo 
community living in the slum areas [75]. 
 
Malaria prevalence is high at 44.7% (as percent of all hospital patients) [22] 
compared to the average national prevalence of 27.7% [76]. Malaria is particularly 
rampant amongst children during the rainy season when breeding grounds for 
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malaria mosquitoes are ubiquitous [76]. The prevalence of Plasmodium falciparum 
infection in children aged 1-4 years has been reported to range between 39% and 
63% [77]. Infant mortality stands at 75 deaths per 1,000 live births while under 5 
mortality is at 105 per 1000 live births [78]. Other diseases affecting infants and 
young children include upper respiratory tract infections and waterborne diseases 
(e.g. typhoid, diarrhoea). HIV prevalence (18.7%) among the adults is the second 
highest in the country [79] and among infants is estimated at 10% [10]. Surveys have 
also shown that the area is endemic for Schistosoma mansoni, with a prevalence of 
14% in infants [80] and infections by hookworm and Trichuris trichiura have 
contributed towards anaemia prevalence in young children [81]. 
 
1.4.7 Selection of study participants (12-36 months old children) 
Children of the age category 12-36 months were selected for this trial for the 
following reasons. First, in full term healthy children (less than 6 months old), iron 
stores obtained from the mother can sustain the infant’s iron requirements; later in 
infancy, the iron demand increases due to rapid growth and subsequent increase in 
blood volume and as such the need for iron increases because the iron stores are 
marginal [82]. Second, most infants are protected against bacterial and parasitic 
infections by antibodies acquired from their mothers during pregnancy and 
transferred by breast-milk but as they grow their immunity develops over time but 
their immune response to eliminate infections depends on the type of bacteria and 
strain that sometimes modify their pathogenicity mechanism to adapt to the host 
defence mechanism [83]. Consequently, severe anaemia (haemoglobin concentration 
<70g/L) is common in children under five years due to infections related to malaria, 
HIV and other parasitic infections. As such, WHO recommends praziquantel and 
benzimidazole antihelmintics (albendazole or mebendazole) to be administered to 
children aged one year and above [83]. Third, breast milk contains low levels of 
para-amine benzoic acid, thus proliferation of malaria parasite is reduced in 
exclusive breastfeeding infants (less than 6 months old) [84]. Consequently, in high 
malaria-endemic areas, the prevalence and density of parasitaemia reaches a peak at 
the age of 6–36 months, and thereafter declines with age [85]. Within this vulnerable 
age range, the incidence peak for severe malaria anaemia precedes that for cerebral 
malaria [86,87]. These children may develop the most severe response to infections 
because they have fewer red blood cells and it is possible that during clearance of the 
uninfected cells clumped to the infected cells the number of red blood cells is further 
reduced [88,89]. These factors either alone or combined underscore the reasons for 
selecting study children who are of the age category 12-36 months. 
 
 
 
1.5 Problem statement  
 
Generally, infants and young children’s need for micronutrients increases because of 
their rapid growth and development. Although there are no statistics showing global 
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prevalence of micronutrient deficiencies, nearly 293 million children globally are 
estimated to have anaemia [4] either due to consumption of plant-based foods that 
are low in micronutrients or incapability to afford animal-rich sources of foods.  
 
In 2011, WHO recommended home fortification with micronutrients including iron 
(12.5 mg, preferably as encapsulated ferrous fumarate) to improve iron status and 
reduce anaemia among infants and children aged 6-23 months. This recommended 
dose of 12.5 mg iron was established to meet almost 90 percent of the estimated total 
iron requirement of children aged 6-18 months [90] and in populations where the 
prevalence of anaemia is ≥20% in children under 5 years of age [4]. Following these 
recommendations, several trials conducted using home fortification with 
micronutrients containing iron (12.5 mg as encapsulated ferrous fumarate) showed 
the iron dose was efficacious in reducing the prevalence of iron deficiency anaemia. 
Conversely supplementation or food fortification with iron at this dose (12.5 mg iron 
ferrous salts) was shown to increase rates of hospital admissions [91], as well as 
diarrhoeal and respiratory diseases [27]. In another trial by Kortman et al. (2012), the 
recommended high iron dose was associated with potentially more pathogenic 
profile at the intestinal epithelial interface [92], leading to an increase in the faecal 
enterobacteria that has been correlated with gut inflammation in African children 
[36]. Ingestion of ferrous salts also frequently causes mild gastrointestinal adverse 
effects (e.g. constipation, nausea, vomiting, and epigastric discomfort) that may 
reduce adherence to treatment [93]. The frequency and severity of such effects 
depend on dose and dosage schedule [94, 95], may be due to oxidative stress [96], 
and appear to be reduced when iron is taken with food. 
 
Thus an assessment of fortification with micronutrient powders containing low 
amounts of iron as 3 mg as NaFeEDTA was undertaken in an attempt to improve 
safety of iron fortification. The chelated form of iron as NaFeEDTA is highly 
absorbable even in high phytate meals and school children with iron deficiency and 
anaemia have been shown to benefit more from fortification with NaFeEDTA when 
compared to placebo or fortification with electrolytic iron [30]. In addition, iron as 
NaFeEDTA has been reported to cause less oxidative stress than an equimolar dose 
of iron as ferrous sulphate [97]. Thus, home fortification with a high dose of iron 
(12.5 mg) as ferrous fumarate when compared to a low dose of iron (3 mg) as 
NaFeEDTA may result in similar or higher amounts of absorbed iron [37], 
suggesting that it may have similar or superior efficacy in improving iron status. If 
this were the case, then low-dose iron as NaFeEDTA would be the preferred choice if 
the reduced amount of free iron in the intestinal tract is shown to be more tolerable 
and associated with better adherence, with less oxidative stress induced by free iron 
in the intestine, and with less intra-luminal iron available to promote propagation of 
potentially pathogenic bacteria with high iron needs. The safety of iron can be 
further improved when given in conjunction with measures to prevent malaria 
parasites and bacterial infections.  
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1.6 Conceptual framework  
 
To maximise the efficacy of iron absorption (both low and high doses) and to 
prevent possible bacterial and parasitic infections associated with effects of iron [14-
16,18,27], an iron intervention that is sustained for several weeks requires a 
protective effect from a long-acting anti-malarial and an anti-helminthic drug..                                                                                                                                         
 
Administration of a curative dose of a slowly eliminated anti-malarial and anti-
helminth drugs results in periods in which subsequent new parasitic infections are 
inhibited by persistent but declining concentrations of the drug (Figure 3 Panel 1). 
With time, blood concentrations of the drugs may fall below the minimal inhibitory 
concentration where parasite growth is possible, but the rate of parasite expansion is 
reduced because of residual drug effect. The iron doses can presumably be safely 
administered during the post-treatment prophylactic period, allowing for the 
restoration and building of iron stores. Upon withdrawal of the interventions, with 
time, body iron stores will become depleted and haemoglobin concentrations will 
start to drop (Figure 3: Panel 2). The duration of protection against anaemia is likely 
to depend on many factors, including the type of antimalarial and anti-helminth 
drugs, the dose and formulation of fortificant iron, duration of the iron intervention, 
initial iron status, and factors that influence iron absorption (e.g. inflammation and 
dietary intake of food compounds). A protection phase is exhibited when infections 
are inhibited by high concentration of the drugs and subsequently iron 
concentrations maintained through restoration and build-up of iron stores. To 
protect against malaria, participating children received a single 3-day therapeutic 
course of dihydroartemisinin-piperquine and to protect against severe anaemia, the 
children received benzimidazole anti-helminthic (albendazole) and praziquantel 
three days before randomization. Also, before randomization day, the medical staff 
conducted medical examinations on all children for parasitic and bacterial infections 
and treated them accordingly. On randomization day the children received the first 
dose of home fortificant with either iron or placebo, this was only administered after 
full completion of the drugs. The minimally desired re-treatment points (figure 3, 
panel 2) were determined based on the duration of protection against anaemia 
following the cessation of home iron fortification after 30 days. 
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Figure 3: Theoretical framework for co-administering home iron fortification and 
intermittent prevention drugs.  
 
 
Thus, the significance of this study is related to the importance of comparing the 
therapeutic effects (efficacy) of two iron formulations (3mg iron as NaFeEDTA 
compared with 12.5 mg iron as encapsulated ferrous fumarate) during time 
windows when children are protected against malaria and other parasitic infections. 
We anticipated that with successful drug treatments and home fortification with 
iron, haemoglobin concentration will substantially increase. Ideally, drug treatments 
and home fortification with iron should be co-administered at a frequency and with 
a duration that allows for the control of anaemia especially in malaria endemic areas.  
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1.7 Study objectives 
 
Overall objective: 
 In children aged 12-36 months, to show non-inferiority of home fortification with 
3mg iron as NaFeEDTA compared with 12.5 mg iron as encapsulated ferrous 
fumarate, with the response in haemoglobin concentration as the primary outcome. 
 
Specific objectives 
1. In children aged 12-36 months, compare daily home fortification for 30 days with 
two iron formulations (3mg iron as NaFeEDTA versus 12.5 mg iron as 
encapsulated ferrous fumarate) regarding:  
a. Haemoglobin concentration at the end of the 30-day fortification period 
(primary objective); 
b. Iron status at the end of the fortification period; 
c. Serum NTBI concentrations at 3 hours after ingesting the first dose of iron 
fortificant; 
d. Faecal calprotectin concentration at the end of the fortification period; 
e. P. falciparum infection at the end of the fortification period as indicated by 
whole blood density of asexual parasites or the presence of antigenaemia; 
f. Adherence to the daily home fortification with iron at the end of fortification 
period. 
 
2. To compare daily home fortification for 30 days with iron (3mg iron as 
NaFeEDTA or 12.5 mg iron as encapsulated ferrous fumarate) versus placebo 
regarding: 
a. The indicators listed under 1a-f; 
b. Time to development of anaemia after cessation of iron fortification. 
 
3. To evaluate the accuracy of self-reported and sachet counts in measuring 
adherence to home fortification and compare with medication events monitoring 
system as a gold standard. 
 
4. To compare effects of iron on intestinal biota (conditional to sufficient resource 
being available). 
 
5.  To identify factors associated with ZPP measured in whole blood or erythrocytes 
     from preschool children and assess the diagnostic performance and utility of ZPP 
     (This objective was decided after field work was completed) 
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1.8 Study outcomes 
 
1.8.1 Haemoglobin concentration (primary outcome) 
Haemoglobin is an iron-binding metalloprotein compound. Over 300 million 
haemoglobin units are found in one red blood cell. The main function of 
haemoglobin is to transport oxygen, which binds to the iron, from the respiratory 
organs and release it to the body tissues where it will in turn collect carbon dioxide 
back to the respiratory organs for exhalation. When the body has insufficient robust 
red blood cells to carry oxygen needed to meet the body’s physiologic needs, 
anaemia occurs [10]. It is estimated that 50% of anaemia worldwide is attributable to 
iron deficiency [100] and the most widely used test for anaemia is haemoglobin 
concentration [101]. Anaemia is not only caused by iron deficiencies, but also by 
infection, vitamin A deficiency, and genetic risk factors like alpha-thalassemia (an 
hereditary anaemic condition caused by impaired production of one or more of 
alpha globin chains that compose the haemoglobin) and sickle cell haemoglobin (a 
hereditary anaemic condition that occurs due to abnormal oxygen-
carrying haemoglobin molecule that gives the red blood cell a crescent-like or moon 
like shape; these abnormal cells lack malleability and can block small blood vessels, 
impairing blood flow). Haemoglobin concentration in the peripheral blood can 
provide information about the severity of the iron deficiency [102] but should be 
used alongside other indicators of iron status because the classifications of 
haemoglobin values for persons with iron deficiency tend to overlap with those who 
are non-anaemic [102]. The only exception is when cost-related constraints for 
conducting bio-chemical assessments for iron deficiency anaemia exist; in that case, 
haemoglobin concentration is often used as a single marker to assess the prevalence 
of iron deficiency in a general population. The recommended WHO cut-off points 
for haemoglobin for children 6-59months are: 110g/l or higher = non-anaemic, 100-
109g/l = mild anaemia, 70-99g/l = moderate anaemia and lower than 70g/l = severe 
anaemia [10]. We estimated the difference in haemoglobin concentrations at the end 
of the 30-day fortification period between groups of children allocated to different 
iron formulations. To determine the effect of treatment on haemoglobin 
concentration after 30 days of intervention we adjusted for study design, baseline 
iron status (haemoglobin concentration, plasma concentrations of ferritin and 
soluble transferrin receptor measured) and inflammation status that are prognosis 
for iron absorption. 
 
1.8.2 Plasma ferritin concentration 
Ferritin, a complex of iron protein, is the principal molecule in which iron is stored 
in the body. It can store intracellular iron safely to prevent the unbound iron from 
toxic interactions [103]. Plasma (or serum) ferritin concentration has been positively 
correlated with the size of the total body iron stores in the absence of inflammation 
[104] which makes it an important indicator of iron status in the body. Ferritin 
concentration varies with sex and age. At birth, ferritin concentration is high and 
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rises within the first two months of life then gradually falls. But at one year of age, 
concentrations begin to rise again and continue to increase into adulthood [105] 
(possible reasons are explained in Section 1.4.7). Elevated plasma ferritin 
concentrations have been found in many chronic inflammatory conditions related to 
infections and, under such circumstances do not reflect the size of iron stores [104] 
because infections stimulate synthesis of ferritin whenever bacteria produce 
endotoxins that up-regulate the gene coding for ferritin. Thus, any observed 
increased levels of ferritin may be interpreted as increased iron stores concealing the 
true iron deficiency status. In Gambian children (18-36 months), ferritin 
concentration was shown to increase with elemental iron supplementation in non-
malaria children and decreased substantially in children had malaria infection 
because of the diminishing inflammatory effect of malaria [106]. 
 
Additionally, plasma ferritin by itself is not a reliable tool for assessing iron status 
during infancy or pregnancy because mean values are often close to the iron 
deficient range, as such should be coupled with other measurements which reflect 
more advanced degrees of iron deficiency [107]. The WHO threshold for diagnosing 
anaemia/depleted iron stores using plasma ferritin concentration remains at <15µg/l 
for individuals 5 years and above and <12 µg/l for children less than 5 years of age 
for both genders. But higher levels <30 µg/l are considered indicative of depleted 
iron in the presence of infections for children under five years of age. In this study, 
we categorised iron status using plasma ferritin as: deficient (plasma ferritin 
concentration < 12 μg/L), replete (plasma ferritin concentration ≥ 12 μg/L in the 
absence of inflammation) or uncertain (plasma ferritin concentration ≥ 12 μg/L in the 
presence of inflammation) [104]. 
 
1.8.3 Soluble Transferrin Receptor (sTfR) 
Transferrin receptor is a membrane-bound, iron-related protein that can be 
expressed on the surface of most types of cells in the body, and that regulates the 
circulation and uptake of iron into all body cells. A soluble form of TfR circulates in 
human serum hence the term soluble transferrin receptor. Transferrin receptor levels 
in the serum are sensitive indicators of the degree of iron deficiency and anaemia 
and a more stable marker of iron levels in an inflammatory state than plasma ferritin 
[104]. In one study, serum sTfR level was shown to detect iron deficiency in 
inflammatory states and in anaemia of chronic disease such as type 1 diabetes [108]. 
Also, it can differentiate between anaemia of chronic diseases and iron deficiency 
anaemia [109]. However, its diagnostic ability is better when in combination with 
other related parameters like plasma ferritin and transferrin saturation. In areas with 
high infection pressure e.g. malaria-endemic areas, the TfR-F index is the best 
predictor of iron deficiency and has specifically been validated experimentally when 
iron stores are based on sTfR/ferritin ratio [110]. 
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However, in this present study we only used plasma soluble transferrin receptor 
concentration (continuous variable) as one of the baseline factors that is associated 
with the primary outcome (haemoglobin concentration) to control for group 
imbalances that are likely to influence the effect estimates of the iron treatments.  
 
1.8.4 Non-Transferrin Bound Iron (NTBI) 
Transferrin is the β-globulin protein synthesized in the liver and located intra-
vascularly. It binds and transports iron as the ferric ion (Fe +3), a form of iron that is 
relatively insoluble at physiological pH and prevents iron from precipitating as 
ferric salts. Transferrin can control the level of free iron in biological fluids, thus 
enabling it to inhibit the growth of gram negative bacteria that need free iron for 
growth. When the iron-binding capacity of transferrin in the plasma of iron 
overloaded patients exceeded >100% transferrin saturation [111], non-transferrin 
bound iron is present in a chelatable low molecular weight form [112]. Again, under 
stress or some pathological conditions e.g. chronic infections such as malaria, a 
release of free iron or non-transferrin bound iron may occur, which is free from its 
protein-bound form [112] and may be toxic because it promotes the growth of 
existing pathogens. Also, the presence of excess oral iron supplementation may 
favour the growth of erythrocytic forms of the malaria parasite [103]. The study 
described in in this thesis originally aimed to examine which of the two daily home 
iron fortifications (3 mg iron as EDTA and 12.5mg as encapsulated ferrous fumarate) 
leads to the highest production of circulating non-transferrin bound iron. However, 
this data is not presented in this thesis because by the time of thesis submission, the 
bio-chemical analysis had not been done due to insufficient funds.  
 
1.8.5. Zinc protoporphyrin-haem ratio 
Zinc protoporphyrin has been used in several studies for measurement of iron 
deficiency. Most of the protoporphyrin in erythrocytes combines with iron to form 
haem but insufficient iron causes zinc to combine with protoporphyrin, forming zinc 
protoporphyrin (ZPP) that can be measured in samples of whole blood [102]. ZPP 
response occurs because iron and zinc interact as the enzyme ferro-chelatase 
substrates and zinc utilization increases whenever iron supply is suboptimal at the 
macrophages [113]. In recent studies, measurement of the ZPP-haem ratio in 
erythrocytes has been used to give the proportion of ZPP compared to the normal 
iron-containing haem in red blood cells and reflects the iron status in the bone-
marrow [114,115]. Although ZPP has often been used in trials as a diagnostic tool for 
detecting iron deficiency, concerns have been raised regarding its ability to 
distinguish between individuals with or without iron deficiency especially in areas 
of low prevalence [116]. Conversely, the ZPP-haem ratio measured directly using 
ZPP-haematofluorometer has been shown to be a simple, accurate and sensitive test 
for detecting early iron depletion before the onset of anaemia but has a limitation of 
being affected by inflammation [117]. In this trial, zinc protoporphyrin-haem ratio 
was measured using ZPP-haematofluorometer (AVIV, model 206D, Lakewood NJ, 
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USA) in whole blood and in erythrocytes as a marker of iron-deficient erythropoiesis 
alongside other iron markers to detect iron deficiency. The ZPP-haem ratio as a 
diagnostic tool either alone or combined with haemoglobin concentration and factors 
that influence its diagnostic ability are presented elsewhere. 
 
1.8.6 C-reactive protein and α1-acid glycoprotein   
Common markers for inflammation include C-reactive protein (CRP), α1-acid 
glycoprotein (AGP), hepcidin and serum ferritin. In this study, we singled out CRP 
and AGP as inflammatory markers because they are acute phase proteins 
synthesised in the liver and respond to cytokines secreted by inflammatory cells. The 
concentrations of CRP and AGP vary with infections and increases rapidly with 
intensity of infection but decreases with disappearance of symptoms. We used a cut-
off plasma concentrations of C-reactive protein and/or α1-acid glycoprotein of 
>5mg/L [118] and >1.0g/L [119], respectively, as markers of the presence of 
inflammation. However, these cut-offs have not been validated in children under 
five years and it is possible that at lower levels of inflammation (CRP<5gm/L and 
AGP <1.0g/L) caused by either chronic infections or low loads of bacteria and 
parasites, hepcidin concentration can be elevated consequently blocking iron 
absorption (Rita Wegmuller, personal communication, May 2016). In our analysis, 
we used the recommended cut-off and considered lower inflammation levels as a 
possible cause for iron blockage to explain varied effects of iron fortification in 
young children.  
 
 1.8.7 Plasmodium infection 
Lack of resources and technical expertise at local health facilities in many African 
countries and in a few other developing countries has resulted to a slow pace of 
detection for Plasmodium infections. As a result, the WHO recommended for the use 
of rapid diagnostic tests to diagnose malaria that has recently yielded tremendous 
benefits as the proportion of reported cases in Africa has risen substantially from less 
than 5% at the beginning of the decade to approximately 35% in 2009. [103]. Rapid 
Diagnostic Tests (RDT) to detect P. falciparum antigen in peripheral blood have high 
sensitivity and are accurate, low-cost, and easily available. Two types of dipsticks 
used in this trial respectively are: 1) Care Start G0151 for P. falciparum-specific lactate 
hydrogenase (pLDH)-based tests detect current infection [120-122] and can 
distinguish between P. falciparum and other Plasmodium species; 2) Care Start G0171 
for histidine-rich protein-2 (HRP2)-based test detects current or recent infection 
because the protein can remain present in the blood for up to several weeks after 
parasitaemia clearance [122], and is specific for P. falciparum only. These tests are 
among the best of 41 brands and types of dipstick tests that were evaluated under 
the auspices of WHO, and have excellent performance (>95%) in detecting low and 
higher parasite density (200 parasites/μL or 2000 parasites/μL, respectively) [123]. 
Also, in this study malaria parasitaemia (using conventional microscopic 
examination) analysis was conducted to detect malaria infection and intensity at 
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three different stages of the study; at baseline and after 30 days of intervention. 
During the post intervention period, blood was stored on DNA collection cards (FTA 
Mini Card) for subsequent assessment by PCR assay of Plasmodium parasites. The 
use of FTA mini cards was considered appropriate as they required less bleeding, 
are easy to use and convenient for storage and transportation for analysis later. 
Confirmation of malaria infection was necessary in supporting the inflammatory 
status at baseline and the end of 30 days of intervention and useful in determining 
the anti-malarial drug (dihydroartemisinin-piperaquine) post-treatment prophylactic 
effect.  
 
1.8.8 Serum concentrations of vitamin B12 and albumin 
Vitamin B12 (cobalamin) is one of the most important vitamins required for 
erythropoiesis alongside other nutrients like folate, vitamin B2 (riboflavin), and iron. 
Measurement of plasma vitamin B12 is essential in this study because in the absence 
of folate (see reasons for omission of folate in Section 1.4.3), vitamin B12 deficiency 
can impair the production of tetrahydrofolate required for thiamine production 
which is fundamentally needed for DNA synthesis during red blood formation 
[102,124]. Whenever DNA synthesis is impaired then large immature and 
dysfunctional red blood cells are formed in the bone marrow thus inhibiting 
haemoglobin synthesis resulting to a condition known as megaloblastic anaemia. 
Megaloblastosis is not expected in children under five years old because it takes 5-10 
years for it to appear due to the body’s capacity to reutilise the vitamin [102]. 
Malabsorption of vitamin B12 is the secondary source of deficiency and is mostly 
caused by loss of parietal cells that produce intrinsic factor. Other causes are 
intestinal lesions, increased bacterial uptake and worm infestation. In this study, we 
assessed the concentration of vitamin B12 with a cut-off set at <150pmol/L [104] to 
determine its deficiency and its association to anaemia as measured by our primary 
outcome (haemoglobin concentration).  
 
Albumin is the most abundant protein in blood plasma and synthesised in the liver. 
It is essential for transporting hormones, fatty acids and other compounds. More 
importantly and in relation to this study, it is a negative acute phase protein and is 
down regulated whenever there is an acute or chronic inflammatory response. This 
mechanism occurs because during inflammation the liver prioritises the synthesis of 
other proteins needed to combat inflammation thus causing the concentration of 
albumin to reduce in the plasma. The relationship between inflammation, serum 
albumin and other acute phase markers (CRP and ferritin) has been shown to have 
an inverse correlation with serum CRP level because C-reactive protein’s 
concentration increases with inflammation (see details in Sections 1.8.6) and has a 
positive correlation with haemoglobin concentration (125). Fundamentally, in the 
absence of systemic inflammation albumin is up-regulated and more iron is likely to 
be absorbed resulting in more haemoglobin synthesis.  
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1.8.9 Measurements of adherence to daily home fortification  
According to Brawley and Culos-Reed (2000), adherence implies that research 
participants are fully involved in behavioural plans and their contributions taken 
into consideration when adjusting research plans. Whereas compliance implies 
behaviour characterized by the extent to which research participants follow 
instructions or use prescriptions as assigned [126], these terms are often used 
interchangeably in clinical studies. Still, measuring adherence in a clinical study or 
treatment setting have potential risks as well as benefit, moreover study participants 
need to be informed about the adverse events, possible side effects, benefits and 
duration of the treatment [50]. 
 
There are several adherence measuring tools, most common are self-reporting, pill 
counts, visual analogue scale, pill identification tests, medication events monitoring 
systems (MEMS) and interviews [3,127] , most of these have been used for 
ambulatory care treatments for asthma, epilepsy, hypertension, HIV, tuberculosis, 
iron deficiency or diabetes among other chronic illnesses. Self- reporting 
questionnaires and sachet counts (either empty or full) are the most common praxis 
for measuring adherence to home-fortification powders because they are easy to use 
and relatively inexpensive, but their reliability and validity have been controversial 
because of various intrinsic factors: a) their sensitivity and specificity outside a gold 
standard is unknown; b) poor reporting is common, because it is either over-
estimated resulting to unknown chances for suboptimal adherence; or it is under-
reported causing it to be misinterpreted as low adherence to treatment [54], and 
subsequently rejection of a treatment that could have otherwise lowered incidences 
of diseases [126], denying an opportunity to decrease global burden of diseases. 
Adherence assessment to home fortification with micronutrients is still under 
investigation and existing evidence is weak [55], but an electronic monitoring and 
time-recording device (MEMS) is suggested to measure adherence for powdered 
micronutrients indirectly estimating frequency and dosage [128] of micronutrient 
intake. Adherence assessment using the MEMS devices is the reference standard [52, 
129,], and is superior to medication pill counts and self-reported questionnaires 
[128,130]. In this study, we set to determine the accuracy of measuring adherence to 
daily home fortification of micronutrient powders using self-reporting 
questionnaires and empty sachet count method compared to the MEMS device. 
 
1.9 Ethical statement 
 
This study was conducted in accordance with the ethical guidelines as laid down in 
the revised Helsinki declaration [131] and the Council for International 
Organizations of Medical Sciences (CIOMS) in collaboration with the World Health 
Organisation [132, 133]. In addition, the Kenyan ethical procedures were used to 
obtain informed consent from communities and individuals participating in the 
study. Ethical clearance was obtained from London School of Hygiene and Tropical 
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Medicine Ethical Committee, UK (6503) and the Kenyatta National Hospital Ethical 
Review Committee, Kenya (KNH-ERC/A/402). The trial was registered with 
ClinicalTrials.gov (NCT02073149). LSHTM acted as the trial Sponsor. 
Implementation was only commenced after approval by both ethical committees and 
consent form signed by parents (Appendix 2). During the study implementation 
there were no major amendments to the protocol.  
 
1.10 Candidate and Co- authors’ contributions 
 
I, Emily Teshome, wish to state that the original concept of this study was conceived 
by Dr. Hans Verhoef and with his guidance I planned the study design. I 
independently conducted all literature review, wrote chapters 1 and 6 and only 
received comments and technical inputs from Professor Andrew Prentice and Dr 
Hans Verhoef where needed. I coordinated the implementation of the research 
project and supervised all field work including staff recruitment, training, data 
collection, data entry into respective computer soft wares and data cleaning. I 
performed all the statistical analysis under the guidance of Dr. Hans Verhoef except 
where I shared responsibility as specified in the respective chapters below. I did not 
perform any laboratory analysis but shared this responsibility as specified in sections 
below.   
 
Chapter 2 and chapter 3 
In both chapters I am the first author, the co-authors to the manuscripts shared 
responsibility as follows: Dr. Pauline Andango assisted in implementing the study 
design; obtaining ethical permits and other research licences in Kenya; procurement 
of project materials and equipment; and assisted in recruitment and supervision of 
research staff. Dr.Walter Otieno was the research project paediatrician and was 
responsible of examining and treating all children with serious adverse events. He 
assisted in recruitment of technical staff and assisted in supervising the clinical 
officers, laboratory technicians and nurses; also, he provided technical support in the 
development of both medical examination and laboratory protocols. Ms. Sofie 
Terwel assisted in development and compiling the study protocol, training the 
research staff, procurement of materials and equipment, and assisted in supervising 
the research staff in the initial stages of implementation. Mr. Victor Osoti assisted in 
supervising human tissue collection, processing, storage, and conducted laboratory 
analysis, packaging and shipping to the Netherlands. In addition, he contributed 
towards procurement of laboratory materials and equipment. Dr. Ayşe Y. Demir was 
responsible for all biochemical analysis of blood samples conducted in the 
Netherlands. Professor Andrew Prentice reviewed the manuscripts and provided 
comments and technical inputs as needed. Dr. Hans Verhoef provided technical 
guidance as needed during study design, study protocol development, Statistical 
Analysis Plan, data analysis and comments during manuscript writing. He also 
analysed data using the metafor package in R software vs. 3.2.0; I was fully involved 
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in the interpretation of the analysed data and writing up of the results. All co-
authors reviewed the manuscripts before submission.  
 
Chapter 4  
As the first author, I designed the study and data collection tools, coordinated field 
work, recruited and trained staff and supervised data collection collaboratively with 
the following: Veronica Oriaro assisted in designing the data collection tools, 
translated the participants’ information brochure (appendix 3), self–reporting form 
(appendix 4) and follow- up checklists (appendix 5) into the local language. Also, she 
assisted in training and supervising research assistants. Dr. Pauline Andango offered 
technical guidance in designing the study design and data collection tools. Dr. Hans 
Verhoef provided technical input in study design and data analysis especially in the 
beta regression using the R- statistical software vs. 3.2.0. Professor Andrew Prentice 
provided comments and technical inputs as needed. All co-authors reviewed the 
manuscript before submission.  
 
 
Chapter 5 
I assisted in the study design, coordinated field work and data collection. Dr. Pauline 
Andango assisted in supervising field work.  Dr. Hans Verhoef conceived the idea, 
provided technical input in the design, and overall supervised all aspects of the 
study. Dr. Ayşe Y. Demir supervised biochemical analyses. Dr. Hans Verhoef and I 
conducted statistical analyses and prepared the first draft manuscript. Professor 
Andrew Prentice reviewed the draft manuscript and provided technical inputs. All 
authors read and approved the final manuscript.   
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Online additional file 1: Statistical analysis plan  
 
Emily Teshome, Hans Verhoef 
 
1. Preamble 
This plan was developed to analyse data from the SEICK (Safe and Effective Iron for 
Children in Kenya) trial. The study received ethical clearance in Kenya (Kenyatta 
University National Hospital/University of Nairobi, #KNH-ERC/A/402)) and in 
England (London School of Hygiene and Tropical Medicine, #6503)), and was 
registered at ClinicalTrials.gov (NCT02073149). The principal features of the planned 
analysis were established as part of the trial proposal. The current plan provides an 
update, was finalised after data collection but before breaking the randomization 
code, and should take precedence over the trial proposal. 
 
 
2. Trial objectives 
The study was primarily conceived to assess non-inferiority of daily home 
fortification with 3mg iron as NaFeEDTA compared with 12.5 mg iron as 
encapsulated ferrous fumarate, with haemoglobin concentration at the end of the 30-
day intervention period as the primary outcome.  
 
The study proposal states the following objectives: 
 
1. In children aged 12-36 months, to compare daily home fortification for 30 
days with two iron formulations (3mg iron as NaFeEDTA versus 12.5 mg iron 
as encapsulated ferrous fumarate) regarding:  
a. Haemoglobin concentration at the end of the 30-day fortification 
period (primary objective); 
b. Iron status at the end of the fortification period; 
c. Serum NTBI concentrations at 3 hours after ingesting the first fortificant 
dose; 
d. Faecal calprotectin concentration at the end of the fortification period; 
e. P. falciparum infection at the end of the fortification period as indicated by 
whole blood density of asexual parasites or the presence of antigenemia; 
f. Adherence to intervention. 
 
2. To compare daily home fortification for 30 days with iron (3mg iron as 
NaFeEDTA or 12.5 mg iron as encapsulated ferrous fumarate) versus placebo 
regarding: 
a. The indicators listed under objective 1a-f; 
b. Time to development of anaemia after cessation of iron fortification. 
 
Page 77 of 169 
 
3. To evaluate the accuracy of self-reported adherence with home fortification, 
using medication events monitoring system as a gold standard. 
 
4. To assess associations between major intestinal parasites and haemoglobin 
concentration at baseline. 
 
5. To compare intervention effects of iron on intestinal biota. 
 
Objectives 1c, 1d, 4 and 5 are conditional to sufficient resources still being found to 
conduct the laboratory analyses required, and will not be further discussed in this 
plan. 
 
3. Study type and key design features 
The study concerns an individually-randomised, controlled non-inferiority trial with 
three parallel arms, with participants randomised to daily home fortification for 30 
days with sachets containing either a) 3 mg iron as NaFeEDTA (experimental 
treatment); b) 12.5 mg iron as encapsulated ferrous fumarate (positive control); or c) 
placebo (negative control). 
 
Demonstration of non-inferiority in a trial with two arms can have two meanings 
only: both interventions are equally effective, or both interventions are equally 
ineffective against placebo. Thus, as per guidelines of the European Medicine 
Agency [1] and the International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use [2], we included a 
third arm with placebo, which allows a) demonstration of superiority of home 
fortification with 3mg iron as NaFeEDTA over placebo (proof of efficacy); b) 
demonstration of superiority of the reference (12.5 mg iron as encapsulated ferrous 
fumarate) over placebo (proof of assay sensitivity); and c) demonstration that the 
home fortification with 3mg iron as NaFeEDTA retains most of the efficacy of the 
reference over placebo (proof of non-inferiority). 
 
Haemoglobin concentration at baseline was strongly expected to be prognostic for 
haemoglobin concentration at the end of intervention. To achieve group balance in 
size and baseline haemoglobin concentration, randomisation was based on a 
stratified block design, with strata defined by baseline haemoglobin concentration 
class (<100 g/L and ≥100 g/L) and randomly sized permuted blocks of 6 or 9. 
Stratification at the stage of randomisation and adjustment for this stratification in 
the analysis was also expected to improve the efficiency of the analysis and the 
precision of the estimated intervention effect. Because of the short recruitment 
period, we did not expect blocks to be associated with haemoglobin concentration, 
even though we could not entirely exclude this possibility (e.g. due to seasonal 
changes in diet or malaria transmission). We did not conduct interim analyses and 
had no stopping guidelines. 
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Figure 1: Summary of study design (not to scale).  
 
 
 
  
 
4. Sample size calculations 
The target sample size was 108 participants per group, which was determined using 
procedures and terminology for sample size calculations in non-inferiority trials as 
recommended by US Food and Drug Administration [3,4]  
a. Based on a meta-analysis [5], we estimated the effect of 12.5 mg ferrous fumarate 
on haemoglobin concentration relative to placebo. The lower limit of the 95% CI 
thus obtained (9.3 g/L) was used as M1, the minimum anticipated effect of 12.5 
mg ferrous fumarate in our trial (Figure 2; left panel). 
 
b. Next, we set M2 as the margin specified to preserve 50% of the anticipated 
minimum effect of 12.5 mg ferrous fumarate anticipated reduction in the 3mg 
NafeEDTA test treatment. This margin (haemoglobin concentration of 4.7 g/L) 
can be interpreted as the largest loss of effect compared to 12.5 mg ferrous 
fumarate (inferiority) that would be acceptable, and also is below an effect for 
5g/L haemoglobin concentration that we consider to be of minimum importance 
for public health. 
R
Premedication
–3 0
Placebo
3 mg iron as NaFeEDTA
12.5 mg iron as ferrous fumarate
30 130
Legend:
Premedication: Praziquantel: single dose; dihydroartemisinin-piperaquine and albendazole: 3-day therapeutic courses 
R: randomisation
* Within each group, the duration of follow-up varied randomly between children between 0 and 100 days after the end 
of the 30-day intervention period; ** With duration corresponding with the arbitrarily selected child who daily received 
12.5 mg iron as ferrous fumarate, as shown under ‘Interventions’
→ Days
Collection of samples
Collection of vital data
*
*
Personal and household data
Monitoring
Medical examination
Anthropometry
Venous blood
Peripheral blood **
Urine and stool
Adherence
Adverse events
Weekly Irregularly
Continuously
Interventions
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c. We set the sample size so that the lower limit of the 95% CI around the difference 
in haemoglobin concentration between the two iron formulations (i.e. 12.5 mg 
ferrous fumarate and 3.0 mg iron as NaFeEDTA) would lie above M2 (Figure 1; 
right panel). 
 
 
 
Figure 2: Theoretical framework for sample size determination 
 
Peer reviewers or editors of scientific journals may demand that we report sample 
size calculations and statistical power. Although such calculations are critically 
important in planning a study, we consider statistical power to be an exclusively 
pre-trial concept, which is irrelevant and conceptually wrong in the interpretation of 
study results, based on assumptions that are not usually met during trial 
implementation, and prone to be misinterpreted by most readers [6,7]. Thus we 
intend to refrain from reporting sample size calculations, but we will report the 
method used to determine the non-inferiority margin. 
 
 
5. Software 
Anthropometric indices will be calculated using WHO Anthro software vs.3.2.2 
(World Health Organisation, Geneva, Switzerland). Data will be double entered, 
checked for completeness and verified for possible entry errors using Microsoft 
Excel. Data cleaning and analysis will be done using SPSS 21 (IBM, Armonk, NY);  R-
software version 3.2.0 (www.r-project.org) and CIA 2.2.0 
(http://www.som.soton.ac.uk/research/sites/cia/and PowerView vs.3.5.2 (AARDEX 
Group ltd, Sion Switzerland) to analyse electronic adherence data. 
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6. Intention-to-treat analysis versus per protocol analysis 
Intention-to-treat (ITT) analysis: Per definition, ITT analysis includes all randomised 
children. It generally is the preferred strategy for data analysis in superiority trials 
(objective 2 above) because a) it tends to avoid over-optimistic estimates of effect in 
real-life conditions, because non-compliers included in the ITT set will generally 
reduce the estimated treatment effect;[8] b) ITT analysis with multiple imputation 
yields valid results when missingness of data is random. Most trials aim to estimate 
the effects of allocating an intervention in real-life conditions, not the effects in the 
subgroup of the participants who adhere to it. 
 
In a non-inferiority trial, however, intention-to-treat analysis is generally not 
conservative because protocol violation and non-adherence to treatment may cause 
the results of the treatment groups to appear similar [9]. 
 
Per protocol analysis: Per protocol analysis is restricted to participants who have 
adhered closely to what is prescribed in the study protocol in the terms of eligibility, 
interventions, and outcome assessment. It does not show the practical value of the 
experimental intervention, but rather envisages determining the biological effect of 
the intervention that can be obtained under ideal circumstances, with participants 
who adhere to trial instructions. However, missing outcome data due to attrition 
(drop-out) during the study or exclusions from the analysis raise the possibility that 
effect estimates obtained by per protocol analysis is biased. Per protocol analysis 
may also raise concerns about data manipulation. 
 
In our study, we will include children in per protocol analysis who received at least 
one dose of home fortification, with exclusion of those not meeting inclusion criteria, 
poorly adhered to intervention, crossed over between intervention groups or 
ingested iron-containing preparations acquired outside the trial, and excluding those 
with missing outcome data. We will define adherence as the number of days that 
home fortificants have been made available relative to the scheduled 30-day 
intervention period, with availability indicated by the electronic device for storage of 
home fortificants having been opened. Poor adherence will be defined as adherence 
< 80% (23 days). This threshold is somewhat arbitrary, but it has been used in most 
published studies on medication adherence [10,11] and we believe that adherence 
above this threshold to be associated with improved iron status. Group adherence 
will be reported as the proportion of participants for whom home fortificants were 
available ≥80% (≥24 days). 
  
Relative importance of intention-to-treat analysis and per protocol analysis: We conceived 
the SEICK trial primarily to be an explanatory trial (i.e. to assess intervention effects 
under optimal conditions) rather than a pragmatic trial (i.e. to assess intervention 
effects under real-life conditions). As per recommendations [12] we will pursue the 
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primary (non-inferiority) objective by comparing results obtained by both intention-
to-treat analysis and per protocol analysis. Non-inferiority will be accepted only if 
efficacy (objective #2), assay sensitivity (objective #2) and non-inferiority (objective 
#1) have all been shown. In our trial report, we will include results of the per 
protocol analysis in the main text, and results of the intention-to-treat analysis as 
supplementary material. 
 
7. Handling of outliers and missing data  
Outliers will be identified by examining a) ranges of continuous variables; b) 
frequency tables of categorical variables; c) visual inspection of scatter plots of pairs 
of continuous variables. Outliers will be dropped only if it is obvious that they are 
due to incorrectly entered or measured data. 
 
Reasons for missing outcome data will be given where possible, coded and reported 
quantitatively as either a) withdrawal of consent; b) adverse events or withdrawn for 
medical reasons (reasons specified); c) no show for follow-up visit(s); d) moved 
away from the study area; e) refused intervention; f) refused to give human tissue 
samples; g) excluded from analysis due to not meeting inclusion criteria; h) excluded 
from analysis due to poor adherence to intervention; i) excluded from analysis due 
to crossing over between intervention groups; j) excluded from analysis due to 
taking iron-containing preparations acquired outside the trial; k) other reasons 
(specified). 
 
For ITT analysis, missing data will be replaced under a missing-at-random 
assumption by multiple imputation (SPSS, ‘automatic’ imputation method; 20 
iterations), with log-transformed variables as necessary to normalize distributions. 
Imputations will be done separately for each of the three intervention groups, with 
datasets derived with these imputed values being merged to allow subsequent 
analysis. All variables used in regression models will be included in the imputation 
model; these will include both baseline factors and outcomes. A list of these 
variables will be reported as supplementary material. 
 
8. Participant flow  
Figure 3 shows the format for presenting the flow of children during the four main 
stages of the trial (enrolment, allocation, follow-up and analysis). For children who 
were excluded before randomisation, reasons will be given where possible, coded 
and reported quantitatively as either a) no show; b) refused to participate; c) no 
written informed consent obtained; d) unlikely to stick to protocol; e) ineligible (with 
reasons specified if possible); f) medical conditions (with reasons specified if 
possible); g) other reasons; h) not known. 
 
Page 82 of 169 
 
 
Figure 3: Flow of study participant (incomplete) 
 
9. Description of group characteristics at baseline 
For continuous variables, we will visually inspect histograms to assess whether they 
are normally distributed within intervention groups, with log-transformation of 
variables with a lognormal distribution. Population characteristics (Table 1) will be 
reported by intervention group as proportions, means (SD), geometric mean 
(geometric SD), and median (25th- and 75th percentiles) as appropriate, with 
corresponding group size. We will not test for group differences for reasons given by 
Assmann et al. (2000)[13].
Assessed for eligibility 
Parents accepted to sign consent forms 
N= 
 
 
 
 
 
Total  excluded = 
1.Chronic infections ( TB, HIV, sickle cell 
anaemia, pneumonia  n= ) 
2. Low Haemoglobin level (<70g/L) n= 
3. Severely  malnourished (<-3SD)  n= 
4.Parent decline (no reasons) n= 
5. Sick children   n=  
6. Child without health card and overage n= 
7.Currently on antimalarial drug n=  
8. Child taken albendazole <1 month prior 
screening day n = 
9. Parent declined human tissues to be 
collected from child  n=  
 
 
 
 
Total eligible for randomization 
n= 
Received malaria chemoprophylaxis and 
home fortificant powder with 12.5mg 
iron as encapsulated ferrous fumarate 
(n== ) 
Loss to follow  (n=  ) 
Parent declined (=   ) 
Child moved residence ( n = ) 
Child was sick (n= ) 
Other reasons (n= ) 
Loss to follow  (n = ) 
Parent declined (n= ) 
Child moved residence ( n= ) 
 Child was sick (n= ) 
Other reasons (n= ) 
Analysed (n= ) 
Excluded from analysis  due to missing 
data (PP*) (n= ) 
Included for analysis ( ITT*) (n=  ) 
Analysed (n= ) 
Excluded from analysis  due to missing 
data (PP*) (n= ) 
Included for analysis ( ITT*) (n=  ) 
Analysed (n= ) 
Excluded from analysis  due to missing 
data (PP*) (n= ) 
Included for analysis ( ITT*) (n=  ) 
 
Loss to follow  (n= ) 
Parent declined (n=  ) 
Child moved residence (n= ) 
Child was sick (n= ) 
Other reasons (n= ) 
 
Received malaria chemoprophylaxis and 
home fortificant powder with no Iron 
(n= ) 
Received malaria chemoprophylaxis and 
home fortificant powder with 3mg iron 
as NaFeEDTA  
(n= ) 
* PP - Per Protocol analysis     *ITT – Intention to treat analysis 
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Table 1: Description of baseline characteristics 
 
Variable Type Units/categories 
Age Continuous months 
Age class Binary 12-23 months, 24-36 months 
Sex Binary %males : %females 
Height-for-age z-score Continuous SD 
Weight-for-height z-score Continuous SD 
Weight-for-age z-score Continuous SD 
Haemoglobin concentration Continuous g/L 
Anaemia status Ordinal Severe to moderate anaemia: haemoglobin concentration <89g/L; mild anaemia: 
haemoglobin concentration 90-109g/L; non-anaemic: haemoglobin concentration 
≥110g/L 
Plasma ferritin concentration Continuous μg/L 
Iron status Nominal Deficient: plasma ferritin concentration <12 µg/L regardless of presence or 
absence of infection or inflammation; replete: plasma ferritin concentration ≥12 
µg/L in the absence of infection or inflammation; uncertain: plasma ferritin 
concentration ≥12 μg/L in the presence of infection or inflammation 
Plasma soluble transferrin receptor 
concentration 
Continuous mg/L 
Plasma C-reactive protein concentration Continuous mg/L 
Plasma α1-acid glycoprotein 
concentration 
Continuous mg/L 
Inflammation Binary Plasma concentrations of C -reactive protein (CRP) > 5mg/L and/or α1-acid 
glycoprotein (AGP) > 1g/L 
Whole blood ZPP concentration Continuous μmol/mol haem 
Erythrocyte ZPP concentration Continuous μmol/mol haem 
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Plasmodium parasite density (asexual 
and sexual forms) 
Continuous µL-1 
Plasmodium infection, by rapid 
dipstick tests 
Nominal No infection; P. falciparum (by HRP2 or P. falciparum-specific pLDH), other 
human Plasmodium spp. (by pLDH), mixed infection 
Urinary hepcidin concentration * Continuous nmol/mmol creatinine 
Plasma folate concentration * Continuous nmol/L 
Plasma vitamin B12 concentration  Continuous pmol/L 
* Funds permitting 
 10. General issues in the analysis of intervention effects 
Effects are measured by comparing outcomes measured after a particular 
intervention with those measured if an alternative intervention has been given 
(counterfactual argument), thus focusing on comparison of end points (instead of 
before-after measurements within groups). We will estimate effects when possible; 
P-values, where reported, will be 2-sided. We will avoid hypothesis testing and 
interpretation of results as ‘significant’ or p<0.05 for reasons reported elsewhere 
[14,15]. 
 
We will describe outcome variables by intervention groups as proportions, means 
(SD), geometric means (geometric SD), and median (25th- and 75th percentiles) as 
appropriate, with corresponding group sizes. For continuous outcomes, these 
estimates will be obtained by ANOVA. 
 
Intervention effects will be assessed as absolute differences (proportions and means) 
or relative differences in geometric means (variables with lognormal distributions) 
between groups, with accounting for the stratified block design. To facilitate 
interpretation, odds ratios resulting from these analyses will be converted to 
differences in proportions. To allow extrapolation of results to other settings, we will 
also consider reporting relative effects for binary outcomes (i.e. proportion ratios). 
Outcomes that are not normally distributed, even after log-transformation, will be 
compared using non-parametric tests (e.g. Mann-Whitney U test, or Wilcoxon rank 
sum statistics) 
 
11. Analysis of the primary outcome (objective 1a and 2) 
Primary analysis: We will estimate the difference in haemoglobin concentrations at 
the end of the 30-day fortification period between groups of children allocated to 
different iron formulations. Non-inferiority will be rejected if the difference between 
groups is less than the non-inferiority margin. 
 
Secondary analysis of the primary outcome will be as follows: 
a. Adjustment for selected baseline variables: Biased effect estimates would occur if 
there are group imbalances in baseline factors that are prognostic for outcome. 
For baseline factors that are known to be strongly, or at least moderately, 
associated with the primary outcome, or for which there is a strong biological 
rationale for such an association, i.e. iron status, plasma soluble transferrin 
receptor concentration, and age, we will evaluate the role of such bias using 
stratified analysis and directly by multiple linear regression models. We also 
expect haemoglobin concentration at baseline to be prognostic for outcome but, 
because this will already be accounted for by adjusting for study design. In 
stratified analysis, we will estimate intervention effects in subgroups formed by 
these baseline factors (for iron status: see definition in Table 1; plasma soluble 
transferrin receptor concentration dichotomised with the median as cut-off value; 
 and age in classes of children aged 12-23 months and 24-30 months) to allow an 
assessment of the validity of model assumptions. In the regression models, we 
will compare effect estimates with and without adjustment by baseline factors 
(plasma concentrations of ferritin and soluble transferrin receptor and age; as 
continuous variables). In the interpretation of data, we will give priority to the 
unadjusted effect, unless the adjusted effect is markedly different (>15%), in 
which case the adjusted effect will be considered the primary analysis. 
 
Subgroup analysis: Because iron absorption is known to depend on iron status, we 
will consider proxy markers for iron status (haemoglobin concentration, plasma 
concentrations of ferritin and soluble transferrin) at baseline as potential 
modifiers for intervention effects.  
 
Stratified analysis will be used to measure effect sizes within subgroups. 
Evidence for group differences in intervention effects will be formally 
investigated in a multiple regression model with main effects (for baseline factors 
and the intervention) and multiplicative interaction terms. 
 
To define subgroups, baseline factors will be categorized (haemoglobin 
concentration class <100 g/L and ≥100 g/L; iron status [see classification above] 
and plasma soluble transferrin receptor concentration [dichotomised, with the 
median as threshold]). For iron status, we will restrict the analysis to a 
comparison of iron-deficient and iron-replete subgroups. 
 
Categorisation of baseline factors has the advantage that results can be 
conveniently presented in a forest plot. It has the disadvantage, however, that the 
precision of the interaction depends on the number and position of the cut-off 
values used to categorise baseline factors [16]. We will also explore interactions 
with baseline factors as continuous covariates, using fractional polynomials [16]. 
Such a strategy is more powerful, especially at towards extreme ends of the 
covariate distribution where limited numbers of observations generally preclude 
detection of interaction, and it may reveal more about the nature of possible 
interactions. We will inspect scattergrams and conduct sensitivity analysis as 
needed to examine the influence of possible outliers on results. 
 
Results of subgroup analyses will be interpreted cautiously for reasons reported 
elsewhere [13].  
 
b. Intention-to-treat analysis: For binary outcomes, pooled estimates from multiple 
iterations may result in non-integer values. This precludes computation of 
confidence intervals for differences in proportions, and may be counterintuitive 
to readers not well versed in multiple imputation techniques. To handle this 
problem, we will calculate differences in means under the assumption of binary 
 outcome variables having a Bernoulli distribution. Pooled chi-squared statistics 
for cross-tabulated data and associated p-values will be calculated as described 
by Van Buuren (2012), thus the p-values obtained are only crude estimates of the 
true values [17].  
 
c. Paired comparisons of iron groups with placebo (objective 2): This analysis will be 
done as for the comparison between iron groups (see above). Superiority will be 
established if no effect is excluded from the 95% CI. 
 
12. Analysis of secondary outcomes (objectives 1b and 2) 
To assess intervention effects, we will conduct all three possible paired comparisons 
between the intervention groups. We will use plasma ferritin concentration as an 
outcome indicator of iron status, and soluble transferrin receptor as an outcome 
indicator of the iron demand by the erythrocytes (both measured at the end of the 
30-day intervention period). We will conduct analysis with and without adjustment 
for baseline factors, as well as intention-to-treat analysis (see methods above). 
 
Plasma ferritin concentration has the limitation that it can be enhanced by 
inflammation independently of iron status. Because our interest in plasma ferritin 
concentration is limited to its value as a marker of iron status, we will adjust all 
analysis for inflammation markers (plasma concentrations of C -reactive protein and 
α1-acid glycoprotein; both as continuous variables) measured at the end of the 30-
day intervention period. Thus we will effectively measure effects on plasma ferritin 
concentration assuming no inflammation. 
 
Similarly, plasma soluble transferrin receptor concentration can be elevated by an 
increased erythropoiesis under influence of malaria-induced haemolysis. Because 
our interest in plasma soluble transferrin receptor concentration is limited to its 
value as a marker of tissue iron demand, we will adjust all analysis for inflammation 
markers (plasma concentrations of C -reactive protein and α1-acid glycoprotein; both 
as continuous variables) measured at the end of the 30-day intervention period. 
 
Stratified analysis will be used to measure effect sizes within subgroups. To assess 
effect modification directly, we will compare multiple logistic regression models 
with and without product terms, with categorical baseline factors entered as 
dummy-coded variables.  
 
 
 13. Multiplicity 
Multiple comparisons to evaluate non-inferiority (section 6) or to measure effects on 
multiple secondary outcomes may raise concerns about multiplicity (i.e. occurrence 
of false-positive results). We consider statistical solutions (e.g. Bonferroni correction) 
to be inappropriate in our trial because a) the concept of multiplicity is rooted in 
hypothesis testing, which is not our framework for making inferences; b) we will not 
formally adjust for multiplicity because any absence or present effect differences will 
be interpreted by the confidence interval in the context of the set thresholds as 
defined in section 6 [14,15,12]; c) for an intervention that leads to multiple changes in 
related outcomes, results from multiple comparisons are mutually reinforcing, not 
mutually debasing [18] . 
 
In case of substantial discordance in results from analyses to evaluate non-
inferiority, we will consider the results to be indeterminate. 
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 Online additional file 2: Effect of home fortification with iron-containing powders 
on anaemia and haemoglobin concentration in preschool children: meta-analysis 
of randomised controlled trials.  
 
Objective: We conducted a meta-analysis of randomised controlled trials in 
preschool children to assess the effect of home fortification with iron-containing 
powders on haemoglobin concentration at the end of intervention.  
 
Methods: This study is an update of the meta-analysis by Salam et al. [1], which 
included trials that provided iron-containing micronutrient powders either in the 
home or at designated centres, with different dosages and duration of intervention. 
Studies that included supporting interventions such as nutrition education were 
included only if the supporting interventions were given to both the intervention 
and comparison groups, so that the difference between the two groups was solely of 
micronutrient powders. We did not follow a review protocol. 
 
To identify studies that were published after the review by Salam et al. [1], we 
conducted a search on Pubmed (https://www.ncbi.nlm.nih.gov/pubmed) with the 
following terms: (Micronutrient* OR ”multiple micronutrient*” OR “multi-vitamin*” 
OR “multi-mineral*” OR “micronutrient powder*” OR MNP OR sprinkle*) AND 
(Fortifi* OR “food fortifi*” OR “point of use” OR “home fortification”) AND 
(hemoglobin OR haemoglobin OR anemia OR anaemia) and with filters: 
Randomized Controlled Trial; Publication date from 2012/11/01 to 2017/03/14; 
Humans; Infant: 1-23 months; Preschool Child: 2-5 years. This procedure yielded 21 
papers. Upon screening titles and abstracts, 15 papers were rejected because they did 
not meet the criteria for inclusion in the present review. We perused the full text of 
the remaining 6 papers, and restricted ourselves to trials that used randomisation at 
the individual or cluster level. We included studies that reported home fortification 
in children aged < 5 years for at least 5 days/week with powders containing ≥10mg 
iron as ferrous salt (i.e. 80% of the 12.5mg iron recommended by the WHO for home 
prevention), or ≥2.0 mg iron as NaFeEDTA (considering that fractional absorption of 
iron added to foods as NaFeEDTA may be 4-5-fold higher than when added as 
ferrous salts [2,3]). We excluded trials with fortificants that were lipid-based or in 
liquid formulations. Authors were contacted to request additional data as necessary. 
 
For each study, we restricted the analyses to haemoglobin concentration measured at 
the end of intervention or change of haemoglobin concentration over time, without 
adjustment for group differences in baseline factors that were predictive for 
outcome, and without adjustments for multiplicity. Differences in means with 
corresponding standard errors were calculated as described by Higgins et al. [4]. 
Cut-off points to define anaemia were as reported by the investigators (haemoglobin 
concentration < 110 g/L). For cluster-randomised trials, standard errors were inflated 
 by the square root of the estimated design effect, D. Such estimates were obtained 
from published reports; if not reported, we used the formula 𝐷 = 1 + (𝑚 − 1) ∙ 𝐼𝐶𝐶, 
where m and ICC are the reported average cluster size and the intra-cluster- 
correlation coefficient, respectively. The ICC was estimated at 0.13 [5]). The analysis 
was implemented using the ‘metafor’ package [6] in R software vs. 3.2.0 (www.r-
project.org). We used random-effects models, with Hartung and Knapp adjustment 
to account for the relatively small number of trials included in the analysis [7], and a 
restricted maximum-likelihood estimator of the between-study variance, τ2. We 
assessed potential reporting bias by visual inspection for asymmetry of the funnel 
plot, and Egger’s regression test. 
 
Results: From the meta-analysis by Salam et al. [1], we excluded two studies that 
were conducted in school children older than 5 years [8,9]. For the study by 
Giovanni et al. [10], we pooled we the two groups that received iron. In the study by 
Sharieff et al. [11], we included the group that received micronutrients with heat-
inactivated Lactobacillus acidophilus, which we pooled with the group that received 
these micronutrients without L. acidophilus. 
 
From our Pubmed search, we excluded three papers because the intervention 
concerned a specially prepared, pre-fortified complementary food [12], children 
received only 120 sachets with micronutrient powders for flexible consumption over 
a supplementation period of 11 months [13], or infants in control group received a 
liquid iron preparation [14]. Thus we identified and included 16 eligible trials 
(including our own) in our meta-analysis [10,11,15-27].  
 
The effect on haemoglobin concentration was highly heterogeneous (I2: 84.1%; p-
value for test of heterogeneity: < 0.0001; Figure 1). The pooled effect on haemoglobin 
concentration was 3.9 g/L (95% CI: 2.2-5.5 g/L), indicating that, in random sample of 
a hypothetically infinite number of trials, each estimating a different true underlying 
effect, one may on average expect an increase in haemoglobin concentration by 3.9 
g/L, with the 95% CI excluding an effect beyond 5.5 g/L. Visual inspection of the 
funnel plot and Egger’s regression test (p=0.44) did not yield evidence for reporting 
bias. 
 
Discussion: We found a high level of heterogeneity in effects across trials. How = 
should we interpret this finding? In the absence of evidence for an effect in single 
trials, meta-analysis is often understood to be the continuation of the pursuit of 
statistical significance by other means. A high level of heterogeneity indicates, 
however, that there is no single true effect in a single, common population that 
underlies the trials included in the meta-analysis. Heterogeneity may reflect 
methodological differences between trials (dosage, formulation and duration of 
intervention, adherence, study quality, etc.) but it may also indicate that there are 
different types of populations, each with different true underlying effects. Thus the 
 pooled random-effect may not reflect the actual effect in any particular population 
being studied, and has little value other than perhaps providing some evidence to 
inform policy decisions. Reassuringly, our meta-analysis (Figure 1) suggests a small 
gain in haemoglobin concentration in most trials, indicating that home fortification 
with iron-containing micronutrient powders provides some benefit across different 
settings. Our trial results illustrate, however, that the evidence may be insufficient to 
recommend home fortification in all settings. Our finding of heterogeneity should 
stimulate subgroup analysis or meta-regression to identify population-specific 
factors that determine efficacy (e.g. differences in prevalence of iron deficiency and 
inflammation, food content of compounds that inhibit iron absorption). Such 
approaches may become possible as evidence is accrued from a variety of studies in 
different settings. 
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 Figure 1: Effect of home fortification with iron-containing powders on 
haemoglobin concentration at end of intervention: meta-analysis of randomised 
controlled trials in preschool children 1 
 
 
Kounnavong et al. (2011) A and B refer to daily or twice-weekly home fortification 
with 10 mg iron, respectively. Soofi et al. (2013) A and B refer to home fortification 
with micronutrient powders excluding and including zinc. Teshome et al. A and B 
refer to effects of 12.5 mg iron as ferrous fumarate and 3 mg iron as NaFeEDTA, 
respectively, as reported by the present study. 
 
1 τ2 (estimated amount of total heterogeneity): 9.55 (95% CI: 4.57, 23.86); I2 (total 
heterogeneity / total variability): 84.1% (95% CI: 71.7%, 93.0%); H2 (total variability / 
sampling variability): 6.29 (95% CI: 3.53, 14.21). Test for heterogeneity: Q (df = 18) = 
102.61, p < 0.0001. 
 Figure 2: Effect of home fortification with iron-containing powders on 
haemoglobin concentration at end of intervention: funnel plot of randomised 
controlled trials in preschool children  
 
Egger’s regression test for funnel plot asymmetry: p = 0.44 
 
 Table 1. Effect of daily home fortification with 3mg iron as NaFeEDTA and 12.5mg iron as encapsulated ferrous fumarate on 
continuous outcomes at 30 days after start of intervention, by intention-to-treat analysis 
 
 
Outcome/intervention group n Estimate a Effect (95% CI) relative to placebo b Effect (95% CI) relative to standard b 
Haemoglobin concentration     
Placebo 112 107.0 g/L (1.3 g/L) Reference Not applicable 
Iron, 3 mg as NaFeEDTA 112 110.0 g/L (1.2 g/L) 3.0 g/L (-0.1 g/L to 6.2 g/L) c 1.3 g/L (-1.8 g/L to 4.3 g/L) c 
Iron, 12.5 mg as ferrous fumarate 114 108.6 g/L (1.2 g/L) 1.6 g/L (-1.4 g/L to 4.7 g/L) c Reference 
Plasma ferritin concentration     
Placebo 112 29.5 μg/L Reference Not applicable 
Iron, 3 mg as NaFeEDTA 112 33.1 μg/L 16.2% (-14.3% to 57.7%) d 2.5% (-22.4% to 35.4%) d 
Iron, 12.5 mg as ferrous fumarate 114 32.5 μg/L 12.3% (-17.1% to 52.0%) d Reference 
Plasma soluble transferrin receptor 
concentration 
    
Placebo 112 2.25 mg/L Reference Not applicable 
Iron, 3mg as NaFeEDTA 112 2.14 mg/L -4.3% (-13.5% to 5.9%) d 3.6% (-5.5% to 13.6%) d 
Iron, 12.5mg as ferrous fumarate 114 2.09 mg/L -7.3% (-16.2% to 2.6%) d Reference 
Erythrocyte ZPP-haem ratio     
Placebo 112 137 μmol/mol [2.17] Reference Not applicable 
Iron, 3mg as NaFeEDTA 112 127 μmol/mol [1.97] -6.5% (-23.5% to 14.2%) d -5.3% (-21.7% to 14.5%) d 
Iron, 12.5mg as ferrous fumarate 114 135 μmol/mol [2.00] -0.7% (-18.6% to 21.0%) d Reference 
a Mean (SE) or geometric mean; b Effects were adjusted for study design (blocks nested within strata of haemoglobin concentration <100 g/L and ≥100 g/L). c 
Effects were calculated as absolute difference in means. d Exponentiation of group differences with log-transformed outcomes resulted in associations being 
expressed as relative differences. 
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Abstract  
 
Introduction: The efficacy of home fortification with iron-containing micronutrient 
powders varies between trials, perhaps in part due to population differences in 
adherence. We aimed to assess to what extent of adherence measured by sachet 
count or self-reporting forms is in agreement with adherence measured by electronic 
device. In addition, we explored to how each method of adherence assessment 
(electronic device, sachet count, self-reporting forms) is associated with haemoglobin 
concentration measured at the end of intervention; and to what extent baseline 
factors were associated with adherence as measured by electronic device. 
 
Methods: 338 rural Kenyan children aged 12-36 months were randomly allocated to 
three treatment arms (home fortification with two with different iron formulations 
or placebo). Home fortificants were administered daily by parents or guardians over 
a 30 day-intervention period. We assessed adherence using an electronic device, self-
reporting and sachet counts. We also assessed haemoglobin concentration at the end 
of intervention.  
 
Results: Adherence, defined as having received at least 24 sachets (≥80%), during the 
30-day intervention period was attained by only 60.6% of children. The 
corresponding values were higher when adherence was assessed by self-report 
(83.9%; difference: 23.3%, 95% CI: 18.8% to 27.8%) and sachet count (86.3%; 
difference: 25.7%, 95% CI: 21.0% to 30.4%). Among children who received iron, each 
10 openings of the sachet storage container were associated with an increase in 
haemoglobin concentration at the end of intervention by 1.15 g/L (95% CI: 0.04 to 
1.92). For each increment in age of the parent or guardian by 1 year, the logit of the 
fractional response increased by 4% (95% CI: 1% to 6%, p=0.002).  
 
Conclusions: Compared to adherence monitoring by electronic device, self-reporting 
and sachet count over a 30-day intervention period was associated with over-
reporting. Adherence to home fortification was associated with the age of the parent 
or guardian. 
 
Key words: 
Adherence; child; preschool; compliance; home- fortification; iron; Kenya; 
medication events monitoring system, sachet count; self-reporting 
Page 102 of 169 
 
4.1 Introduction 
 
In 2011, WHO recommended home fortification with iron-containing micronutrient 
powders (1). The basis of this recommendation was a meta-analysis of randomised 
controlled trials showing moderate quality evidence for an effect on anaemia and 
haemoglobin concentration (2). In a recent placebo-controlled trial, however, we 
failed to find effects of home fortification with iron-containing micronutrient 
powders on either anaemia or haemoglobin concentration. In addition, in an 
updated meta-analysis, we showed that the magnitude of the effect on haemoglobin 
concentration varied between trials (Teshome, et al, submitted). Such variability in 
trial results may be due in part to population differences in adherence to home 
fortification. Adherence has been assessed in several trials by self-reporting (or 
proxy reporting, in the case of guardian reporting for children in their care) and 
sachet counts. Although these assessment methods are easy to use and relatively 
inexpensive, their reliability and validity are controversial (3). Both frequently result 
in overestimation of adherence because study participants respond in a manner that 
they believe is socially desirable but conceals their actual behaviour, or participants 
may consciously or unconsciously fail to return unused medication. Poor recall, 
particularly over long periods, can also lead to underreporting and underestimation 
of adherence (3-5). 
 
Medication event monitoring system (MEMS) although expensive is superior to 
medication counts and self-reporting adherence method [6-7] and has been 
considered to be the reference standard in several trials [8-9]. We are not aware of 
studies that used MEMS devices to measure adherence to home fortification with 
micronutrient powders.  
 
We aimed to assess to what extent of adherence measured by sachet count or self-
reporting forms is in agreement with adherence measured by electronic device. In 
addition, we explored to how each method of adherence assessment (electronic 
device, sachet count, self-reporting forms) is associated with haemoglobin 
concentration measured at the end of intervention; and to what extent baseline 
factors were associated with adherence as measured by electronic device. 
4.2 Subject and Methods 
 
Study design  
This report concerns a secondary analysis of an explanatory, individually-
randomised, placebo-controlled non-inferiority trial to assess the effect of daily home 
fortification on haemoglobin concentration and iron status. We measured adherence 
over the 30 day-intervention period using MEMS, self-reporting and sachet counts. 
Details regarding study methodology are available in the study protocol (Teshome et 
al, submitted). 
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Study area and participants 
The study was conducted in 3 administrative areas of Kisumu West, Kenya in the 
period between January and December 2014.  A total of 433 children aged 12-36 
months were invited by field workers to the research clinic for screening and their 
parents signed informed consent forms. During the screening period, medical staff 
verified their ages by birth certificates or health cards, conducted medical 
examination, took anthropometric measurements (height and weight), and collected 
venous blood (4mL) in tubes containing Li-heparin after 30 days of intervention for 
subsequent determination of haemoglobin concentration (HemoCue 301, 
Ängelholm, Sweden). 
 
Children who attained the following admission criteria were randomised: aged 12‒
36 months; resident in the study area and parents intending to stay in the area in the 
subsequent nine months; child had no twin; parental consent form signed by both 
parents; not acutely sick or febrile (axillary temperature ≤37°C) at the time of 
recruitment; absence of reported or suspected major systemic disorder; haemoglobin 
concentration ≥70 g/L; not severely wasted (weight-for-height z-score <‒3 SD); no 
known allergy to dihydroartemisinin-piperaquine, benzimidazole or praziquantel; 
no reported history of using anti-helminth drugs in the 1-month period before the 
screening date; not at risk of malaria (e.g. because children had received 
chemoprophylaxis). 
 
To protect children against malaria and severe anaemia during the intervention 
period, we administered pre-medications to every eligible child at the end of the 
screening visit. We gave a therapeutic course of dihydroartemisinin-piperaquine 
(Sigma-tau, Rome, Italy; target dose: 40mg dihydroartemisinin/320mg piperaquine), 
albendazole (Indoco Remedies, Mumbai, India) and praziquantel (Cosmos, Nairobi, 
Kenya) [1, 10]. 
 
Interventions and follow-up 
Three days after starting pre-medication, parents were asked to bring their child 
again for a visit to the research clinic, where children were randomly allocated to 
receive daily home fortification for 30 days with micronutrient powders containing: 
a) 3mg iron as NaFeEDTA versus, or b) 12.5 mg iron as encapsulated ferrous 
fumarate, or c) placebo (no iron). The micronutrient powders were manufactured 
specifically for this trial by DSM Nutrition Products (Johannesburg, South Africa) 
and packaged in 1g sachets. The home fortificant powders for all three groups 
contained the same multiple micronutrients other than iron (table 1) as 
recommended by the Home Fortification Technical Advisory Group, except folic 
acid, which we omitted because of our concerns that it may be utilized by 
Plasmodium parasites and increase failure risk of antifolate drugs [11,12] 
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The micronutrient powders were packed in 1-gram plain white foil single-serve 
sachets that were identical in appearance and that did not result in apparent 
differences in taste, texture or colour of uji (maize gruel, a local food commonly 
given to young children). The MEMS device comprised of a white plastic bottle with 
an electronic cap and had no other marker except the serial number, label with the 
child’s identification number, date of start and end of intervention period. Except for 
the trial coordinator and one field supervisor, neither parents nor research assistants 
were informed about the function of the electronic device. Instead they were 
informed that the MEMS cap is essential for maintaining the moisture content and 
good hygienic conditions of the micronutrient powders. 
 
The research assistants gave parents a supply of 30 sachets in a plastic bottle with a 
MEMS cap and instructed them to daily add the contents of one sachet to the child’s 
semi-solid, ready-prepared foods for a period of 30 days. The first dose of the 
treatment was administered at the research clinic. Parents were shown how to mix 
the micronutrient powder with uji. Parents were trained by the research assistants to 
fill out the self–reporting form (Appendix 4) and were instructed to fill out the form 
each day after the child completed consuming a meal containing the micronutrient 
powders. They were shown how to pack the empty sachet in empty zip-lock plastic 
bag provided to them and instructed to immediately report any sickness or adverse 
reactions experienced by the child during the intervention period. Each child was 
issued with a plate, a spoon and a mug to minimise sharing of the sachet content. A 
return date to the research clinic was written on the self-reporting forms, plastic bag 
and MEMS bottle, and parents were verbally informed about this return date.  
 
Research assistants conducted weekly pre-announced home visits (one visit per 
child per week) making a total of 3 visits per child, these visits were denoted as 
“regular monitoring” to check if the child was still in the study area, if parents were 
following protocol when administering the fortificants, if sachets were still in MEMS 
device (research assistants were instructed not to open the bottle during the home 
visits but to gently shake the bottle to ascertain the contents), and to check if parents 
were filling out forms and storing empty sachets. Also, the research assistants 
discussed problems or clarified procedures, but they did not give parents 
instructions additional to those given during the randomisation visit. All 
observations and problems experienced by parents were recorded in a home-visit 
report form and submitted to the field supervisor at the end of each day. Sick 
children were referred to the research clinic. 
 
Parents were asked to bring their children again to the research clinic at the end of 
the 30-day intervention period, where phlebotomists collected blood and performed 
point-of-care tests (including haemoglobin concentration) using the same procedures 
as in the screening visit. Research assistants collected all the adherence-measuring 
tools.  
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Description of adherence measuring tools 
 
Medication events monitoring system (MEMS): Electronic monitoring system provides 
detailed information in the timing of the events e.g. day, correct time intervals and 
per cent prescribed doses taken [13]. We used an electronic monitoring and time-
recording device (MEMS 6 TrackCap 45mm without LCD display; 
http://www.mwvaardex.com/) that was given for the duration of the study to 
parents of participating children. This battery-operated device consists of a cap that 
fit the bottle, with a built-in microprocessor that records and stores date and time of 
all openings. Each bottle had a capacity of holding 30 micronutrient sachets, and was 
labelled with a child’s identification number, serial number of the electronic cap, 
name of child, start and end date for ease of identification and tracking. Parents were 
thoroughly instructed to open the bottle only when removing the sachet and to close 
it immediately after each opening. The research assistant demonstrated this 
instruction when the first dose of powder was administered at the research clinic. 
The information recorded in the MEMS cap was downloaded and stored 
electronically in the computer.  
 
Sachet counts: We defined sachet count as the number of empty sachets stored after 
intervention period. The empty sachet is a proxy indicator that child has consumed 
the content of a full sachet. Research assistants instructed parents to securely keep 
empty sachets in a zip-lock plastic bag marked with the child’s name and 
identification number. On their return visit to the research clinic, parents returned 
the empty sachets contained in zip-lock plastic bag plus any left-over full sachets in 
the MEMS device. The research assistant immediately counted and recorded the 
empty sachets into the Excel spread sheet. The leftover full sachets remained in the 
MEMS bottle and were only removed after the MEMS data had electronically been 
transferred to power-view software. The number of full sachets was manually 
recorded in the MEMS software power view data sheet in order to verify if the 
number of times MEMS cap was not opened matched the number of full sachets.   
 
Self-reporting form: We used a 1-page self-reporting form that was simple and easy to 
fill out by a parent, even with low level of primary education. The form had a simple 
chart that allowed a parent to easily tick a box whenever a full sachet of 
micronutrient powder was administered to the child, either in the morning, mid-
morning, lunch, mid-afternoon or evening. The form was translated into the local 
language (dholuo).  
  
 4.3 Definition of endpoints 
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Adherence to treatment was defined as the number of days within the intervention 
period that the electronic monitoring device was opened, the number of empty 
sachets within the intervention period, or the number of days within the 
intervention period that the child received home fortification as reported by the 
mother or guardian. High adherence was defined as adherence ≥80% (24 days or 
more). This threshold is arbitrary, but is often used in published studies on 
medication adherence [7, 13-16]. Low-adherence was defined as adherence < 80% (23 
days or less) [17].  
4.4 Statistical analysis 
 
Analysis was conducted using SPSS 21 (IBM, Armonk, NY), WHO Anthro software 
vs.3.2.2 (World Health Organisation, Geneva, Switzerland), Power View vs.3.5.2 
(AARDEX Group ltd, Sino, Switzerland) and R-software version 3.2.0 (www.r-
project.org). CIA (https://www.som.soton.ac.uk/research/sites/cia/download/),   
For children who did not complete intervention because parents refused 
supplementation after randomisation, or because of unknown reasons, we retained 
30 days of intervention or 30 sachets as denominators of these proportions. For 
children who were lost to follow-up during the intervention period because they 
moved out of the study area, we initially intended to censor the observation period 
at the day that the child was lost and to use proportional weights to account for 
differences in observation time between children. However, since we could not 
establish the day that these children moved, we excluded them from the analysis.  
 
Differences in proportions of children with high adherence were compared by 
Newcomb’s method for paired samples. To evaluate agreement in adherence, 
measured as continuous variables between various assessment methods, we used 
scatter plots with corresponding Pearson’s product-moment correlation coefficient, r. 
We used t-tests and linear regression analysis to model haemoglobin concentration 
at the end of 30 days of intervention as a function of adherence. In these analyses, we 
excluded children who received placebo.  
 
Lastly, we used simple beta regression analysis with a logit link to identify variables 
that were associated with adherence as measured by MEMS device. In this analysis, 
we transformed the adherence outcome variable so that fractional response values of 
0 or 1 were replaced using the formula 𝑦′ = [𝑦 + (𝑛 − 1) + 0.5]/𝑛 [17] with y being 
the fractional response, and n being the sample size. The variables examined 
included experimental treatment, baseline characteristics of the child (sex, age, being 
infected by P. falciparum, wasting, stunting), the child being sick during the 30-day 
intervention period, and characteristics of the parent or guardian (age, gender, 
education level). 
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. 4.5 Results 
 
Participant flow and baseline characteristics 
The profile of trial participants and reasons for loss to follow are presented in Figure 
1. Of the 433 children invited for screening at the research clinic 339 were eligible but 
within the first few days of the intervention one child was excluded because she had 
a twin sister. 23 children were lost to follow-up: parents or guardians from eight 
children refused further cooperation, six children moved residence, and nine 
children were lost for unknown reasons. 15 participants failed to submit their self-
reporting forms, 13 participants did not return empty sachets, one electronic cap was 
damaged and another was lost. All parents who declined to continue with the study 
submitted their measuring instruments and gave permission for data collected to be 
included in the study. 
 
Table 2 presents the baseline characteristics. We included more boys than girls (186 
versus 152), mean age (SD) was 23.6 ±6.5 months and the distribution of children by 
age class was evenly distributed between the intervention groups. At baseline, the 
mean (SD) haemoglobin concentration was 105 (3.2) g/L and 62.1% (209/338) of the 
children were anaemic. The prevalence of being stunted, wasted and underweight 
were 30.2% (102/338), 2.9% (10/338) and 13.6% (46/338), respectively. Mean (SD) age 
of primary guardians was 27.4 (6.3) years ranging from 16 to 50 years. Interviews 
conducted at end of study (post intervention) showed that about 80.2% (158/197) of 
the mothers administered the sachets at home; in other cases, the child’s older 
siblings (9.1%), extended family members (6.1%) or father (4.1%) took up this role. 
Most primary guardians 71.2% (141/197) attained upper primary education level 
followed by secondary education level 20.8% (41/197), lower primary education level 
5.5% (11/197) and very few 2.5% (5/197) attained tertiary level of education. At the 
end of 30 days of intervention, the mean (SD) haemoglobin concentration was 108.5 
(12.7) g/L and the prevalence of anaemia was about 46%. 
 
Adherence as measured by self-reporting, sachet counts and MEMS device 
MEMS data indicated that 60.6% of children received at least 24 sachets during the 
30-day intervention period (Table 3). Such high adherence was more frequently 
indicated by both self-report (83.9%; difference: 23.3%, 95% CI: 18.8% to 27.8%) and 
sachet count (86.3%; difference: 25.7%, 95% CI: 21.0% to 30.4%) than recorded by 
MEMS (Table 3). This over-reporting by self-report and sachet count was apparent 
when inspecting the scatterplots of results obtained by these methods with those 
obtained MEMS data (Figure 2). The value for Pearson’s r expressing the strength of 
the correlation between adherence by self-report and MEMS device was 0.39 
(p<0.001), whilst the corresponding value for the correlation between adherence by 
sachet count and MEMS device was 0.38 (p<0.001). 
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Adherence and haemoglobin concentration at the end of iron intervention 
Among 228 children who received home fortification with iron, formulated either as 
ferrous fumarate or NaFeEDTA, the mean haemoglobin concentration at the end of 
intervention was 109.3 g/L (SD: 12.2 g/L), with a corresponding prevalence of 
anaemia of 44.3% (n=101). 
   
Within children who received iron, we could identify an association between 
haemoglobin concentration at the end of the 30-day intervention period and 
adherence as assessed by MEMS (p=0.04), but not when assessed by self-report or 
sachet count (p=0.11 and p=0.14, respectively) (Table 4). Each 10 openings of the 
sachet storage container were associated with an increase in haemoglobin 
concentration of 1.15 g/L (95% CI: 0.04 to 1.92).  
 
When adherence was assessed by MEMS, we found that children with high 
adherence to home fortification with iron had higher haemoglobin concentration at 
the end of the 30-day intervention period than their peers with low adherence 
(111.1g/L versus 106.6g/L; difference: 4.6g/L, 95% CI: 1.2g/L to 8.0g/L). There was no 
evidence for such an association when adherence was assessed by self-report 
(109.7g/L versus 107.0g/L; difference: 2.7g/L, 95% CI: -1.6g/L to 7.0g/L) or sachet 
counts (109.6g/L versus 107.3g/L; difference: 2.2g/L, 95% CI: -2.6g/L to 7.1g/L). 
 
Factors associated with adherence measures using MEMS device  
Adherence to home fortification was associated with the age of the parent or 
guardian: for each increment in age by 1 year, the logit of the fractional response 
increased by 4% (95% CI: 1% to 6% p=0.002; Figure 3). Compared to adherence with 
home fortification with placebo, there was no evident difference in adherence with 
home fortification with iron, either as NaFeEDTA or as ferrous fumarate. We also 
found no evidence that adherence was affected by baseline characteristics of the 
child (sex, age, being infected by P. falciparum, wasting, stunting), the child being 
sick during the 30-day intervention period, or characteristics of the parent or 
guardian (gender, education level) (Table 5).  
 
4.6 Discussion 
 
Compared to adherence monitoring by electronic device, we found that self-
reporting and sachet count over a 30-day intervention period was associated with 
over-reporting. Among children who received iron, haemoglobin concentration at 
the end of the 30-day intervention period was associated with adherence as assessed 
by MEMS, but there was no evidence of it being associated with adherence as 
assessed by self-report or sachet count. Each 10 openings of the electronic device 
were associated with an increase in haemoglobin concentration of 1.15 g/L (95% CI: 
0.04 to 1.92). Adherence to home fortification was associated with the age of the 
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parent or guardian, but we found no evidence that it was associated with home 
fortification with iron or any other baseline characteristics for child or parent. 
 
We assume that assessment of adherence by electronic device is more reliable than 
by self-report or sachet count. This seemed confirmed by our finding that adherence 
assessed by MEMS was associated with a haemoglobin concentration response in 
children who received iron, whereas such a response could not be shown when 
adherence was assessed by self-report or sachet count. Our findings are similar to 
results of a randomized trial that showed MEMS caps opening data positively 
reflected actual adherence and a positive effect to hypertensive treatment among the 
African-Americans [14]. However, we cannot exclude the possibility that there were 
parents who administered missed doses on the next day in addition to the scheduled 
dose. Compared to ingestion of a single dose of non-haem iron, multiple dosing 
leads to a decrease in the proportion of iron absorbed, but an increase in the absolute 
amount of iron absorbed [17]. Thus the efficacy of missing a dose and doubling it on 
the next day is probably in between the efficacy of regular daily dosing and skipping 
a missed dose altogether. In that case, assessment of adherence by sachet count may 
theoretically be better than by electronic device. 
 
As reported elsewhere, we failed to find an effect of home fortification with either 
3mg iron as NaFeEDTA or 12.5mg iron as ferrous fumarate on haemoglobin 
concentration, erythrocyte zinc protoporphyrin or plasma iron markers (Teshome, et 
al, submitted). This failure may have been due in part to the relatively short 
intervention period, consumption of diets containing high phytate and phenolic 
compounds and in part to infection-associated inflammation, which was highly 
prevalent in our study population. In the present study, we found that adherence, as 
assessed by MEMS, showed only 60.6% of children consumed at least 80% (≥24) 
sachets during the 30-day intervention period. These data, coupled with our finding 
that adherence was associated with haemoglobin concentration at the end of the 30-
day intervention period; indicate that sub-optimal adherence may also have 
contributed to our failure to show efficacy. 
 
The association between age of the parent or guardian and adherence to home 
fortification should be interpreted with caution, because this finding was the result 
of exploratory analyses. Nonetheless, this finding supports results of a trial 
conducted among HIV-infected adults in Los-Angeles, where older age was 
associated with higher adherence rates of anti-retroviral adherence [18] compared to 
the younger patients. Therefore, it is possible that in our present study the older 
parents are better carers and attempted to observe the instructions given for the use 
of MEMS device, potentially improving the adherence measurement when 
compared to the younger carers. Further trials are needed that are specifically 
designed to identify and understand determinants of adherence to home fortification 
of micronutrient powders. In such trials, latent class analysis [19] may be helpful to 
Page 110 of 169 
 
define subgroups on the basis of beliefs and attitudes about home fortification at 
baseline. 
 
A strong point of our study is the use of beta regression analysis to model adherence 
expressed as a fractional response. Linear regression analysis of the untransformed 
fractional response is commonly used but has limitations: a) the effect of explanatory 
variables tend to be non-linear, particularly with responses towards the extremes of 
the range [0, 1]; b) a proportion is not normally distributed (even though a normal 
approximation may be reasonable if all observations are reasonably close to 0.50); 
and c) the variance is not constant but varies with the outcome, meaning it is 
maximised at a population proportion of 0.50 and it shrinks when the population 
proportion approaches one of the boundaries. Similar problems are likely to arise 
when estimating adherence as the mean fractional response, or when comparing 
groups by the mean difference in fractional response using ANOVA or assuming t-
distributions. 
 
In conclusion, compared to adherence monitoring by electronic device, self-reporting 
and sachet count over a 30-day intervention period was associated with over-
reporting. Adherence to home fortification as measured by MEMS device was 
associated with the age of the parent or guardian 
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Table 1: Formulation of micronutrient powders (study formulation) 
Micronutrient 
 
Content 
Vitamin A, μg RE 300 
Vitamin D, μg 5 
Vitamin E, mg 5 
Vitamin C, mg 30 
Thiamin (vitamin B1), mg 0.5 
Riboflavin (vitamin B2), mg 0.5 
Niacin (vitamin B3),mg 6 
Vitamin B6 (pyridoxine), mg 0.5 
Vitamin B12 (cobalamine), μg 0.9 
Iron 
 
EITHER iron as encapsulated ferrous fumarate, mg 12.5 
OR iron as NaFeEDTA, mg 3 
OR no iron (placebo) 0 
Zinc, mg 5 
Copper, mg 0.56 
Selenium, μg 17 
Iodine, μg 90 
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Table 2: Baseline characteristics  
Characteristic Placebo 
Iron, 
3mg as NaFeEDTA 
Iron, 
12.5mg as ferrous 
fumarate 
n 112 112 114 
General characteristics    
Sex, male 69 (61.6%) 61 (54.5%) 56 (49.1%) 
Age, months 22.8 (6.8) 23.2 (6.2) 24.9 (6.4) 
Age class     
12-23 months 61 (54.5%) 57 (50.9%) 44 (38.6%) 
24-36 months 51 (45.5%) 55 (49.1%) 70 (61.4%) 
Nutritional markers    
Haemoglobin concentration, g/L 104.4 (13.2) 105.9 (13.3) 104.7 (13.3) 
Anaemia    
Moderate (haemoglobin concentration 70–99.99 g/L) 33 (29.5%) 34 (30.4%) 36 (31.6%) 
Mild (haemoglobin concentration 100–109.99g/L) 39 (34.8%) 31 (27.7%) 37 (32.5%) 
No anaemia (haemoglobin concentration ≥ 110g/L) 40 (35.7%) 47 (42.0%) 41 (36.0%) 
Anthropometric markers    
Body height, cm 80.9 (5.9) 82.1 (5.7) 82.4 (5.1) 
Body weight, kg 10.6 (1.8) 10.8 (2.0) 10.9 (1.7) 
Stunted (height-for-age z-score < –2 SD) 34 (30.4%) 31 (27.7%) 37 (32.5%) 
Wasted (weight-for-height z-score < –2 SD) 3 (2.7%) 5 (4.5%) 2 (1.8%) 
Underweight (weight-for-age z-score < –2 SD) 19 (17.0%) 12 (10.7%) 15 (13.2%) 
Values indicate n (%), mean (SD)  
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Table 3: Adherence as indicated by various methods during the 30-day 
intervention period 
 
Adherence MEMS 
(n=338) 
Self-reporting 
(n=338) 
Sachet count 
(n=338) 
Coverage a 330 (97.6%) 317 (93.8%) 313 (92.6%) 
Missing b 8 (2.4%) 21 (6.2%) 19 (5.6%) 
High (≥ 80% or ≥ 24 sachets 
consumed)  
200 (60.6%) 266 (83.9%) 270 (86.3%) 
Low (<80% or 1-23 sachets 
consumed) 
130 (39.4%) 51 (16.1%) 43 (13.7%) 
Values indicate n (%), MEMS= Medication Events Monitoring System 
a Number of children that consumed at least one of the 30 sachets scheduled during 
the intervention period.  
b Missing data as follows: MEMS = data from 6 participants were excluded because 
they moved residence, 1 participant damaged electronic device and another lost the 
electronic devices; Self-reporting = data from 6 participants were excluded because 
they moved residence and 15 others failed to submit their self-reporting forms; 
Sachet counts = data from 6 participants was excluded because they moved resident 
and 13 others failed to return empty sachets.  
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Table 4: Association between adherence and haemoglobin concentration in 
children who received daily home fortification with iron as ferrous fumarate or 
NaFeEDTA 
 
Adherence 
assessment method 
Difference in haemoglobin concentration, g/L 
(95% CI) a 
P-value 
MEMS 1.15 (0.04 to 1.92) 0.04 
Self-reporting 2.33 (-0.50 to 5.16) 0.11 
Sachet count 2.69 (-0.88 to 6.27) 0.14 
MEMS: Medication Events Monitoring Systems 
 
a Association expressed as the mean difference in haemoglobin concentration for 
each increment in adherence by 10 MEMS openings, or 10 sachets consumed as 
indicated by self-report or sachet count.   
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Table 5: Baseline characteristic associated with measures of adherence by MEMS 
device  
 
Baseline Characteristic Estimate SE p-value 95%CI-L 95%CI-H 
Intervention           
Placebo 1.24797 0.11100 
Referenc
e     
NaFeEDTA 0.11084 0.14720 0.451 -0.177672 0.399352 
Ferrous fumarate 0.07503 0.14651 0.609 0.2121296 0.3621896 
Sex           
Male 1.25617 0.08981 
Referenc
e     
Female 0.12123 0.12076 0.315 0.1154596 0.3579196 
Age            
Age of child (days) 0.00000 0.00003 0.922     
Parents Age (years) 0.03761 0.01218 0.002 0.0137372 0.0614828 
Morbidity           
Sick 0.00886 0.13993 0.950 0.2654009 0.28311292 
P. falciparum infection -0.15645 0.12415 0.208 -0.399784 0.086884 
Nutritional indicators           
Wasting 0.06404 0.05851 0.274 0.0506396 0.1787196 
Stunting 0.05756 0.04326 0.183 0.0272296 0.1423496 
Underweight 0.08083 0.05200 0.120 -0.02109 0.18275 
Education level           
None 1.76250 0.33190 
Referenc
e     
Upper primary -0.54270 0.33790 0.108 -1.204984 0.119584 
Secondary -0.26150 0.36530 0.474 -0.977488 0.454488 
Tertiary -0.19690 0.63060 0.755 -1.432876 1.039076 
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Figure 1: Participants flow chart 
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Figure 2: Adherence measurements as assed by self-reporting and sachet tools 
compared with MEMS device.  
 
 
Panel A: Data were not available for 17 children because 15 self-reporting forms 
were either missing or not filled out and records of 2 MEMS devices missing because 
1 device was damaged and another was not returned at end of 30 days after 
randomization. Panel B: Data were not available for 15 children because 13 children 
lost or did not returned empty sachets and 2 MEMS devices were unavailable. Not 
all data points in Panel A and Panel B are visible due to over-lapping of adherence 
counts. The red line indicates perfect agreement in adherence counts between pairs 
of assessment methods. For each panel, data points presented above the reference 
line indicate overestimation of adherence assessed by self-report or sachet count, 
respectively, as compared to adherence measured by MEMS, whereas data points 
presented below the reference line indicate underestimation of adherence measured 
by MEMS.  
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Figure 3: Age of parent as predictor of measure of adherence to daily home 
fortification 
 
 
 
 
The blue diagonal line shows for each increment in age by 1 year, the logit of the 
fractional response increased by 4%.  
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Abstract 
 
Zinc protoporphyrin has often been used in trials as a diagnostic tool for detecting 
iron deficiency, however, concerns have been raised regarding its ability to 
distinguish between individuals with or without iron deficiency especially in areas 
of low prevalence and little is known regarding its diagnostic utility either alone or 
combined with haemoglobin concentration in young children. We aimed to a) 
identify factors associated with zinc protoporphyrin (ZPP) in children aged 1-3 
years; b) assess the diagnostic performance and utility of ZPP, either alone or in 
combination with haemoglobin, in the identification of iron deficiency. 
Methods: We used baseline data from 338 Kenyan children enrolled in a 
community-based randomisedtrial ,  To identify factors related to ZZP measured in 
whole blood or erythrocytes we used multiple linear regression analysis. To assess 
diagnostic performance, we excluded children with elevated plasma concentrations 
of C-reactive protein  α1-acid glycoprotein , and Plasmodium infection. In addition,  
we analysed receiver operating characteristics (ROC) curves, with plasma ferritin 
concentration <12μg/L as the reference for iron deficiency. We also developed 
models to assess the diagnostic utility of ZPP and haemoglobin concentration when 
used to screen for iron deficiency. 
Results: Whole blood ZPP and erythrocyte ZPP were independently associated with 
haemoglobin concentration, Plasmodium infection and plasma concentrations of 
soluble transferrin receptor, ferritin, and C-reactive protein. In children without 
inflammation or Plasmodium infection, the prevalence of true iron deficiency was 
32.1%, compared to prevalence of 97.5% and 95.1% when assessed by whole blood 
ZPP and erythrocyte ZPP with conventional cut-off points (70μmol/mol and 
40μmol/mol haem, respectively). Addition of whole blood ZPP or erythrocyte ZPP to 
haemoglobin concentration increased the area-under-the-ROC-curve (84.0%, 
p=0.003, and 84.2%, p=0.001, respectively, versus 62.7%). A diagnostic rule 
(0.038689[haemoglobin concentration, g/L] + 0.00694[whole blood ZPP, μmol/mol 
haem] >5.93120) correctly ruled out iron deficiency in 37.4%-53.7% of children 
screened, depending on the true prevalence, with both specificity and negative 
predictive value ≥90%. 
Conclusions: In young children, whole blood ZPP and erythrocyte ZPP have added 
diagnostic value in detecting iron deficiency compared to haemoglobin 
concentration alone. A single diagnostic score based on haemoglobin concentration 
and whole blood ZPP can rule out iron deficiency in a substantial proportion of 
children screened. 
 
Trial registration: NCT02073149 (25 February 2014) 
 
Key words: Erythrocyte protoporphyrin; inflammation; iron deficiency; Kenya; 
malaria; Plasmodium; child, preschool; zinc protoporphyrin
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5.1 Background 
 
Zinc protoporphyrin (ZPP) is formed in erythrocytes when the iron supply for 
erythropoiesis is less than required, or when iron utilization is impaired. In such 
conditions of iron-deficient erythropoiesis, protoporphyrin IX, the immediate 
precursor of haem, incorporates an atom of zinc rather than iron, resulting in the 
formation of ZPP instead of haem. Thus depleted iron stores or a decrease in 
circulating iron in the bone marrow lead to elevated ZPP concentrations in whole 
blood or erythrocytes [1, 2]. 
 
ZPP can be determined rapidly and at low assay cost by haematofluorometer. It has 
been used to screen and manage iron deficiency in individual children, but at a 
population level, it has also been a recommended marker for iron status in cross-
sectional studies, together with haemoglobin concentration [1, 3].  
 
We found earlier, however, that both whole blood ZPP and erythrocyte ZPP have 
little diagnostic utility as a screening marker to manage iron deficiency in pregnant 
women, whether used as single tests or combined with haemoglobin concentration 
[4]. 
 
The present study aimed to identify factors associated with ZPP measured in whole 
blood or erythrocytes from preschool children. We also assessed the diagnostic 
performance and utility of ZPP, either alone or in combination with haemoglobin 
concentration, in detecting iron deficiency defined as plasma ferritin concentration 
<12 μg/L in children without inflammation or Plasmodium infection. 
 
5.2 Methods 
 
The study was conducted from January–December 2014 in Kisumu-West District, 
Kenya, and received ethical clearance both in Kenya (Kenyatta University National 
Hospital, reference KNH-ERC/A/402) and in England (London School of Hygiene 
and Tropical Medicine, reference 6503). In order to recruit the children, community 
health workers compiled a list of parents with children aged 1-3 years in the study 
area and invited parents to bring these children for screening to the research clinic, 
where they were asked to sign an informed consent form.  Weight and height were 
determined using Salter Scale (UNICEF, catalogue 0145555, Copenhagen, Denmark) 
and height/recumbent length boards (UNICEF, catalogue 0114500, Copenhagen, 
Denmark) within 100g and 1 mm, respectively.   
 
A total of 338 children aged 12-36 months were recruited into the study. We 
included children if: resident in the study area; parental consent form signed by both 
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parents; not acutely sick or febrile (axillary temperature ≥37.5°C) at the time of 
recruitment; absence of reported or suspected major systemic disorder (e.g. HIV 
infection, sickle cell disease); no use of antiretroviral drugs against HIV, rifampicin, 
carbamazepine, phenytoin or phenobarbital and no twin sibling. Children were 
excluded if: haemoglobin concentration <70 g/L; severely wasted (weight-for-height 
z-score <‒3 SD); known allergy to dihydroartemisinin-piperaquine, benzimidazole or 
praziquantel; parent-reported history of using antihelminthic drugs in the 1-month 
period before the screening date; not at risk of malaria (e.g. children who received 
chemoprophylaxis against malaria because of HIV infection or sickle cell disease); 
did not complete the second and third doses of dihydroartemisinin-piperaquine.  
 
Phlebotomists collected venous blood in tubes containing Li-heparin. We assessed 
haemoglobin concentration (HemoCue 301, Ängelholm, Sweden) and zinc 
protoporphyrin: haem ratio (AVIV haematofluorometer, model 206D, Lakewood NJ, 
USA) in whole blood as a marker of iron-deficient erythropoiesis, each in triplicate. 
An aliquot of blood was centrifuged, plasma was transferred to a microtube, 
centrifuged, and stored immediately in liquid nitrogen (-196 °C). The erythrocyte 
sediment was washed and centrifuged three times with isotonic phosphate-buffered 
saline to allow measurement in triplicate of the erythrocyte zinc protoporphyrin: 
haem ratio. Rapid diagnostic tests were used to detect Plasmodium falciparum-specific 
lactate hydrogenase (pLDH), and P. falciparum-derived histidine-rich protein-2 
(HRP2). Further details are reported elsewhere. 
 
Plasma iron indicators (concentrations of ferritin and soluble transferrin receptor), 
inflammation indicators (concentrations of C-reactive protein, α-1-acid glycoprotein) 
and other nutritional markers (concentrations of albumin and vitamin B12) were 
measured on an Abbott Architect C16000 and i2000 SR analyser with reagents from 
and as per instructions of the manufacturer. 
5.3 Statistical analysis 
 
Anthropometric indices were calculated by comparing measurements with the 
standards WHO Growth Standards [5]. For whole blood and erythrocyte ZPP, we 
used a cut-off value of 70 μmol/mol haem (2.7 μg/g haemoglobin), corresponding to 
the 95% upper limit of the reference values for women and children participating in 
the US National Health and Nutrition Examination Survey (NHANES) II, from 
which individuals with anaemia, low transferrin saturation and elevated blood lead 
concentrations had been excluded [1-3]. For erythrocyte ZPP, we also used a cut-off 
point of 40 μmol/mol haem, which is based on several small studies comparing iron-
deficient and iron-replete individuals [6, 7]. 
 
We defined iron deficiency as the absence or near-absence of storage iron, indicated 
by plasma ferritin concentration <12 μg/L [8]. Because this definition is 
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recommended by WHO to measure population iron status except where 
inflammation is prevalent [2], we considered it to be valid only in children without 
inflammation, Plasmodium infection, or HIV infection. In addition, we used the 
following definitions: anaemia = haemoglobin concentration < 110 g/L [9]; 
inflammation = plasma concentrations of CRP > 5 mg/L [10] and/or AGP > 1 g/L [11]; 
being stunted or wasted = height-for-age or weight-for-height z-score < -2 SD; [5] P. 
falciparum infection = presence in blood of HRP2 or P. falciparum-specific pLDH; any 
Plasmodium infection = presence of HRP2 or pLDH specific to either P. falciparum or 
human Plasmodium species other than P. falciparum; low vitamin B12 status = plasma 
vitamin B12 concentration <150pmol/L. 
 
Description of the study population 
We calculated prevalence values for binary variables, means with corresponding 
SDs for variables with an approximately normal distribution, and quartiles for 
continuous variables that were not normally distributed. Because some of the 
plasma markers used (ferritin, albumin, vitamin B12) can act as acute phase reactants 
we also described these characteristics in children without inflammation or 
Plasmodium infection.  
 
Factors associated with ZPP 
We explored associations between ZPP and personal characteristics (age, sex), 
inflammation markers, iron markers, Plasmodium infection and other plasma 
markers (albumin and vitamin B12 concentrations). Groups were compared assuming 
t-distributions of ZPP values that were normalised by log-transformation. 
Exponentiation of results yielded group differences that were expressed as relative 
differences. 
 
We inspected scatterplots and used simple linear regression analysis to assess 
associations between ZPP (log-transformed) and explanatory variables with 
continuous outcomes. Some explanatory factors were untransformed, with the 
implicit assumption that ZPP values can increase or decrease exponentially with an 
absolute increment in the explanatory variable; in other cases, log-transformation of 
the explanatory factor yielded a better model fit, indicating that ZPP values and 
explanatory variables change at rates that are proportional to their current values. In 
such cases, variation in the independent variable was expressed as geometric 
standard deviation, i.e. a dimensionless, multiplicative factor such that dividing or 
multiplication of the geometric mean by this ratio indicates a variation that is 
equivalent to subtraction or addition of one standard deviation on a log-transformed 
scale [12]. 
 
We subsequently used multiple linear regression analyses to identify factors that 
were independently associated with ZPP. Given a linear association between 
continuous variables, dichotomisation generally results in loss of statistical precision 
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[13]. Thus we preferred to use continuous variables that were shown to be linearly 
associated with ZPP in the bivariate analyses. Our analysis started with a full model 
that included haemoglobin concentration, Plasmodium infection, and plasma 
concentrations of ferritin, soluble transferrin receptor, CRP, AGP, albumin, vitamin 
B12, sex (binary) and age class (binary). All plasma markers except albumin and 
vitamin B12 were log-transformed. Factors were manually eliminated using a 
backward elimination process with a removal criterion of p>0.05. 
 
Diagnostic performance of ZPP to detect iron deficiency  
This part of the analysis was restricted to children without inflammation (i.e. plasma 
concentrations of CRP > 5 mg/L and/or AGP > 1 g/L) and without Plasmodium 
infection. We used logistic discriminant analysis to model the probability of iron 
deficiency as a function of continuous explanatory variables, either alone or 
combined.  
 
We used the pROC package [14] within R vs. 3.2.0 (www.r-project.org) to produce 
and analyse receiver operating characteristics (ROC) curves, with comparison of 
areas-under-the-curve (AUCs) by DeLong's test for paired curves. Partial AUCs 
were computed with a correction to achieve a maximal value of 1.0 and a non-
discriminant value of 0.5, whatever the range of specificity or sensitivity values. 
Confidence intervals of estimates for partial areas-under-the-curve (pAUCs) were 
computed by stratified bootstrapping with 10,000 replicates.   
 
Diagnostic utility of ZPP to estimate prevalence of iron deficiency 
First, we assessed the diagnostic performance of ZPP to estimate the prevalence of 
iron deficiency, using two commonly used cut-off points for ZPP, namely whole 
blood ZPP >70 μmol/mol haem and erythrocyte ZPP >40 μmol/mol haem (see 
preceding paragraphs). We used Wilson’s method to calculate confidence intervals 
around proportions [15, 16]; for sensitivity and specificity, and for the pair of 
predictive values, we calculated 97.5% univariate CIs. The cross-product of these 
univariate CIs, considered together, form a joint 95% confidence region for both 
population parameters [17]. 
 
Second, as an example, we used our data to explore the utility of using the 
combination of haemoglobin concentration and ZPP to screen for iron deficiency 
(Additional file 1), with cut-points chosen to ensure a high sensitivity so that most 
cases are detected, at the cost of false positives that could be eliminated by further 
diagnostic tests. Children can be excluded from further testing if negative test results 
correctly identify children without iron deficiency in the vast majority of cases. Such 
a strategy may be desirable in community-based surveys with relatively low 
prevalence of iron deficiency, but also in medical practice with higher prevalence 
values (because of self-selection). Thus we estimated the proportion of children who 
could be eliminated from further testing in settings with a prevalence range for iron 
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deficiency of 0%-50%, which probably covers the vast majority of community 
settings, with arbitrarily selected sensitivity values and negative predictive values of 
>90%. Because of its ease of measurement, we limited this assessment with ZPP 
being measured in whole blood. 
5.4 Results  
 
Description of the study population  
The prevalence of iron deficiency, measured in children without inflammation or 
Plasmodium infection, was 32.1%; when measured in all children (Table 1), this value 
was 17.1%. Whole blood ZPP > 70 μmol/mol haem occurred in 97.9% and 
erythrocyte ZPP > 40 μmol/mol occurred in 96.7% of children. The prevalence of 
anaemia was 62.1%, but there were virtually no children with low vitamin B12 status. 
Inflammation, assessed by plasma concentrations of C-reactive protein and α1-acid 
glycoprotein, occurred in 66.9% of children, and was mostly mild. Of 226 children 
with inflammation, 98 (43.4%) had elevated concentrations of α1-acid glycoprotein 
with normal C-reactive protein concentrations, 11 (4.9%) had elevated C-reactive 
protein concentrations with normal concentrations of α1-acid glycoprotein, and 117 
(51.8%) had elevated concentrations of both markers. Of children who carried 
Plasmodium parasites (36.4%=123/338), only 1 was infected with Plasmodium species 
other than P. falciparum. 
 
Factors associated with ZPP: crude analysis  
In bivariate analysis, both whole blood and erythrocyte ZPP were strongly elevated 
in iron deficiency, anaemia and Plasmodium infection; they declined with increasing 
haemoglobin and plasma ferritin concentrations; and they increased with plasma 
transferrin receptor concentration (Table 2). Whole blood ZPP was also associated 
with increased plasma concentrations of α1-acid glycoprotein and C-reactive protein 
concentration; a higher prevalence of inflammation as defined by α1-acid 
glycoprotein > 1 g/L; decreased plasma albumin concentration, and increased plasma 
vitamin B12 concentration. Although erythrocyte ZPP was reduced in children aged 
24-36 months and, seemed higher in boys than in girls, there was no evidence that it 
was associated with inflammation, however defined, or with either of the two 
plasma inflammation markers. We found no evidence that ZPP, whether measured 
in whole blood or erythrocytes, was associated with z-scores for height-for-age or 
weight-for-height, or with being stunted or wasted. 
 
Factors associated with ZPP: multiple linear regression analysis  
In multivariate analysis, there was no evidence that ZPP, whether measured in 
whole blood or erythrocytes, was associated with plasma concentrations of α1-acid 
glycoprotein and vitamin B12, or with sex or age class. Thus these factors were 
eliminated from the models shown in Table 3. 
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Whole blood ZPP was independently associated with decreased concentrations of 
haemoglobin and ferritin and with increased plasma concentrations of transferrin 
receptor and C-reactive protein (Table 3). Of all biochemical markers, plasma 
transferrin receptor concentration showed the strongest association with whole 
blood and erythrocyte ZPP. Similar results were found with erythrocyte ZPP as 
dependent variable. Plasmodium infection was associated with elevated whole blood 
ZPP, and an even more pronounced elevation in erythrocyte ZPP values. There was 
a mild association between plasma albumin concentration and erythrocyte ZPP, but 
retention of this factor in the model for whole blood ZPP did not appreciably change 
the magnitude of the association for other factors. 
 
Diagnostic performance of ZPP to detect iron deficiency  
ROC curve analysis showed that whole blood and erythrocyte ZPP had similar 
diagnostic performance (AUC values: 79.1% and 81.2%, respectively; p=0.36) in 
detecting iron deficiency, but either marker performed better than haemoglobin 
concentration (AUC: 62.7%) (Figure 1A; Table in Figure 1). The diagnostic accuracy 
was further improved by combining either whole blood or erythrocyte ZPP with 
haemoglobin (Figure 1B, p=0.003; and Figure 1C, p=0.001, respectively). 
 
Overall, there was no evidence that the diagnostic accuracy differed between the 
combination of haemoglobin concentration with erythrocyte ZPP and the 
combination of haemoglobin concentration with whole blood ZPP (AUCs: 84.2% 
versus 84.0%; p=0.91). The ROCs for these markers crossed (Figure 1D) at a 
sensitivity of 81.5%, corresponding to 0.07195[Hb] + 0.01449[ZZPwhole] = 10.39334 
(where Hb and ZPPwhole indicate haemoglobin concentration in g/L and whole blood 
ZPP:haem ratio in μmol/mol, respectively; in this equation, parameter estimates are 
shown with 5 decimals to avoid misclassification due to multiplication of rounding 
errors). At all sensitivity values above this cut-off (Figure 1D, red rectangle), the 
diagnostic accuracy of the combination of erythrocyte ZPP with haemoglobin 
concentration was superior to the combination of whole blood ZPP with 
haemoglobin concentration (corrected pAUCs: 76.3% versus 70.4%, p=0.04). 
 
Diagnostic utility of ZPP 
When whole blood ZPP was considered without additional markers to detect iron 
deficiency, a conventional threshold of 70 μmol/mol haem resulted in the following 
estimates (Table 4): sensitivity: 100%; specificity: 3.7%, positive predictive value: 
34.2%; prevalence: 97.5% (as compared to a ‘true’ prevalence of 32.1%; Table 1). 
Corresponding values for an erythrocyte ZPP threshold of 40 μmol/mol haem were: 
100%, 7.4%, 35.1% and 95.1%. 
 
Within a prevalence range of iron deficiency of <14.1%, a diagnostic rule of 
haemoglobin concentration > 122 g/L would rule out iron deficiency in 14.1%-14.8% 
of children tested, depending on the actual prevalence, with both sensitivity and 
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negative predictive value > 90% (Figure 2). Similarly, within a prevalence range of 
iron deficiency of < 28.6%, whole blood ZPP > 99 μmol/mol haem would rule out 
iron deficiency in 28.6%-36% of children tested; and within a prevalence range of 
37.4%, 0.038689 [Hb] + 0.00694 [whole blood ZPP] > 5.93120 would rule out iron 
deficiency in 37.4%-53.7% of children. At all prevalence values exceeding these 
ranges, these diagnostic tests would not be able to rule out children with the 
predefined diagnostic criteria (i.e. both sensitivity and negative predictive value 
should be 90%), and all children would need to undergo further diagnostic work-up 
using more advanced tests.  
 5.5 Discussion 
 
In our population, virtually all children had whole blood ZPP values exceeding 
conventional cut-off points of 70 μmol/mol haem, resulting in very low specificity 
and gross overestimates of the ‘true’ prevalence of iron deficiency of 32.1%, whether 
assessed in the overall population or when restricted to those without inflammation 
and without Plasmodium infection. A similar problem was noted with erythrocyte 
ZPP > 40 μmol/mol haem. Both whole blood ZPP and erythrocyte ZPP were 
independently associated with Plasmodium infection and plasma C-reactive protein 
concentration. ZPP, whether measured in whole blood or erythrocytes, yielded 
higher diagnostic accuracy in detecting iron deficiency than haemoglobin 
concentration alone, and also improved this diagnostic accuracy when used in 
combination with haemoglobin concentration. When applied in a screen-and-treat 
strategy to control iron deficiency in paediatric populations with a prevalence of iron 
deficiency of <37.4% (which covers most settings in developing countries), our data 
suggest that a diagnostic rule of 0.038689 [Hb] + 0.00694 [whole blood ZPP] > 5.93120 
can correctly identify 90% of children with iron deficiency, and correctly rule out 
iron deficiency in 37.4%-53.7% of children who are tested, depending on the true 
prevalence. 
 
We found a particularly strong relationship between ZPP, whether measured in 
whole blood or erythrocytes, and plasma transferrin receptor concentration. This is 
not surprising because both are markers for iron-deficient erythropoiesis. Consistent 
with our data, ZPP is known to be increased in iron deficiency, inflammation and 
other causes of an inadequate iron supply to erythroblasts. The increase in whole 
blood ZPP that was associated with Plasmodium infection may be due in part to the 
formation of bilirubin and other haemoglobin breakdown products in plasma that 
result from haemolysis and that fluoresce in the same wavelength range as 
protoporphyrins. Plasmodium infection was also associated with an even larger 
increase in erythrocyte ZPP, independently of inflammation. This was unexpected 
because erythrocytes lack plasma constituents, which are removed by washing. A 
possible explanation is that haemolysis-induced increase in erythropoietin activity 
under influence of Plasmodium infection drives up the demand for iron in the 
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erythron. We have not been able to find previous reports of an association between 
erythrocyte ZPP and plasma albumin concentration, which could be a spurious 
finding. 
 
One limitation of our study is the difficulty of measuring iron status in the presence 
of inflammation. Throughout the remainder of this discussion, it should be noted 
that we assessed the diagnostic performance and ZPP in children without 
inflammation and without Plasmodium infection, because plasma ferritin 
concentration can be elevated in the presence of infection-induced inflammation 
independently of iron status. We used this approach in favour of other biomarkers 
and approaches that have been proposed. 
 
In one method [18,19], fixed correction factors for serum ferritin concentrations are 
computed based on geometric mean values in groups that are defined by cross-
classification of individuals by two inflammation markers (serum concentrations of 
C-reactive protein > 5 g/L and α1-acid glycoprotein > 1.0 g/L). The resulting ratios in 
geometric mean values are used to adjust individual values, and deficiency is 
determined on the basis of these adjusted values. This method has the 
disadvantages, however, that it is not validated using a reference standard, its 
validity depends on untested and perhaps invalid assumptions, and it does not take 
into account likely between-person variability in the response of ferritin 
concentration to inflammation. Recently, it has been proposed to adjust values using 
regression analysis [11]. Although this approach offers several theoretical 
advantages, its validity remains to be investigated by comparison with a reference 
standard. The ratio of concentrations of soluble transferrin receptor/log ferritin has 
been suggested as a marker of body iron content but its use to detect iron deficiency 
remains problematic for reasons discussed elsewhere [4]. 
 
Our results clearly show that, in the absence of inflammation or Plasmodium 
infection, ZPP has added diagnostic value in detecting iron deficiency over 
haemoglobin concentration alone. This added value applied both to ZPP measured 
in whole blood or erythrocytes. By contrast, we found that the diagnostic 
performance of haemoglobin concentration in detecting iron deficiency was similar 
in pregnant women (AUC: 61%, [4]) as in children (AUC: 63%, present study); in 
pregnant women, however, replacement of haemoglobin concentration by ZPP, or 
addition by ZPP to haemoglobin concentration, whether measured in whole blood 
or in erythrocytes, had little diagnostic value [4].   
 
When combined with haemoglobin concentration, whole blood ZPP or erythrocyte 
ZPP yielded AUC values for the ROC curves of approximately 84%. Whether this 
accuracy is satisfactory depends on the purpose of testing. Conventional cut-off 
points for whole blood ZPP and erythrocyte ZPP are clearly inappropriate and 
produce gross overestimates of prevalence and a very low positive predictive value 
Page 132 of 169 
 
(Table 5 in this paper; see also [4]) due to their low specificity. Mwangi et al 2014 [4], 
reported how cut-off points can be manipulated to minimize bias in the estimation of 
population prevalence. In the present paper, we have shown how cut-off points for 
haemoglobin and whole blood ZPP, either alone or in combination, can be calibrated 
in a screen-and-treat strategy to identify individuals with iron deficiency at 
community level. Screening generally requires the selection of a cut-off point to 
ensure a high sensitivity for the test or combination of tests to be employed. Such 
high sensitivity ensures that most cases are detected, at the cost of false positives that 
can be eliminated by further diagnostic tests. Although the accuracy of this approach 
is insufficient to give a final diagnosis in all individuals, the combination of 
haemoglobin concentration and whole blood ZPP can constitute a rapid and 
convenient method to rule out iron deficiency in a substantial proportion of children 
screened. Although we considered the example of screening at community level, a 
similar strategy can be employed in clinical practice to identify children who may 
need referral to higher levels of care for further testing. When 0.07195[Hb] + 
0.01449[ZZPwhole] < 10.39334, the diagnostic accuracy may be improved by using a 
combination of erythrocyte ZPP with haemoglobin concentration, but the improved 
diagnostic accuracy thus achieved must be weighed against the procedure of 
washing red cells, which may be cumbersome in practice. 
 
One problem that has not been solved in our study is the difficulty in detecting iron 
deficiency in the presence of inflammation. The associations found between ZPP and 
Plasmodium infection and between ZPP and C-reactive protein, underscore the 
importance of this issue. Further research is required to extend and validate our 
approach with appropriately selected reference standard for iron deficiency in a 
population that included individuals with inflammation and infections. Because 
point-of-care tests are rapidly developing, with quantitative tests already being 
commercially available for plasma concentrations of ferritin and C-reactive protein, 
and for various infections, this is likely to be a fruitful area of future research. 
 
Conclusion 
In Kenyan preschool children, ZPP, whether measured in whole blood or in 
erythrocytes, has added diagnostic value in detecting iron deficiency over 
haemoglobin concentration alone. When used in a screen-and-treat approach, 
combination of haemoglobin concentration and whole blood ZPP in a single 
diagnostic score can be used as a rapid and convenient testing method to rule out 
iron deficiency in a substantial proportion of children screened. 
 
Abbreviations 
AGP: α1-acid glycoprotein; AUC: Area-under-the-curve; CRP: C-reactive protein; EP: 
Erythrocyte protoporphyrin; FEP: Free erythrocyte protoporphyrin; Hb: 
haemoglobin concentration; HRP2: Histidine-rich protein-2; IPT: Intermittent 
preventive treatment; pLDH: Plasmodium lactate dehydrogenase; ROC: Receiver 
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On line additional file 1: The utility of haemoglobin concentration and ZPP as 
diagnostic tests to screen and rule out iron deficiency 
 
Consider the example of a community survey in which children are screened for iron 
deficiency, with treatment being restricted to those who are iron deficient.  
 
In the absence of inflammation, serum ferritin concentration < 12 μg/L is 
recommended by WHO to measure iron status in paediatric populations [2]. 
Although commercial point-of-care tests for serum ferritin concentration have 
recently become available, its measurement is often difficult under field conditions 
and relatively expensive. A screening strategy whereby haemoglobin concentration 
and whole blood ZPP are used to rule out iron deficiency would be useful and could 
possibly lead to substantial cost savings. 
 
Let the result of a diagnostic test (i.e. haemoglobin concentration and ZZP, used 
alone or in combination) be dichotomized. Table 1 shows the cross-tabulated data 
that might be obtained. 
 
Table 1. Cross-tabulated data for true iron status and diagnostic test results 
 
Diagnostic test 
result 
Iron deficient (reference) Total 
Yes No 
Positive A B U 
Negative C D V 
Total R T N 
Capital letters in each cell indicate the number of individuals in that cell 
 
The aim of screening is to detect most cases of iron deficiency, i.e. with a cut-point of 
the test result selected to ensure a high sensitivity (e.g. >90%). Because a high 
sensitivity comes at the cost of a reduced specificity, this will inevitably result in 
false positives that could be eliminated by further diagnostic tests. The advantage of 
screening with a high sensitivity, however, is that iron deficiency can be effectively 
and with near-certainty be ruled out in those with a negative test result [20]. 
 
Let the negative predictive value (NPV = D/V) be set to ensure that a high proportion 
of negative test results (e.g. >90%) are correct. The NPV can be rewritten as a 
function of the prevalence, sensitivity and specificity: 
 
𝑁𝑃𝑉 =
𝐷
𝑉
=
𝑇 ∙ 𝑆𝑝𝑒𝑐
𝐶 + 𝐷
=
(𝑁 − 𝑅) ∙ 𝑆𝑝𝑒𝑐
𝑅 ∙ (1 − 𝑆𝑒𝑛𝑠) + (𝑁 − 𝑅) ∙ 𝑆𝑝𝑒𝑐
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Dividing both numerator and enumerator by N yields: 
 
𝑁𝑃𝑉 =
(1 − 𝑃) ∙ 𝑆𝑝𝑒𝑐
𝑃 ∙ (1 − 𝑆𝑒𝑛𝑠) + (1 − 𝑃)𝑆𝑝𝑒𝑐
 
 
Thus, at a sensitivity of 90% and corresponding specificity derived from the ROC 
curves (Figure 1), a NPV > 90% can be obtained only within a certain prevalence 
range. 
Similarly, the positive predictive value (NPV = A/U) can be formulated as a function 
of the prevalence, sensitivity and specificity: 
 
𝑃𝑃𝑉 =
𝑃 ∙ 𝑆𝑒𝑛𝑠
𝑃 ∙ 𝑆𝑒𝑛𝑠 + (1 − 𝑃) ∙ (1 − 𝑆𝑝𝑒𝑐)
 
 
The fraction with a negative test result (F = V/N) for whom iron deficiency can be 
ruled out can similarly be rewritten as a function of the prevalence or pre-test 
probability (P = R/T), sensitivity (Sens = A/R) and specificity (Spec = D/T) as follows: 
 
𝐹 =
𝑉
𝑁
=
(𝐶 + 𝐷)
𝑁
=
𝑅 ∙ (1 − 𝑆𝑒𝑛𝑠) + 𝑇 ∙ 𝑆𝑝𝑒𝑐
𝑁
=
𝑅 ∙ (1 − 𝑆𝑒𝑛𝑠)
𝑁
+
(𝑁 − 𝑅) ∙ 𝑆𝑝𝑒𝑐
𝑁
 
 
Thus: 
𝐹 = 𝑃 ∙ (1 − 𝑆𝑒𝑛𝑠) + (1 − 𝑃) ∙ 𝑆𝑝𝑒𝑐 = 𝑆𝑝𝑒𝑐 + 𝑃 ∙ (1 − 𝑆𝑒𝑛𝑠 − 𝑆𝑝𝑒𝑐) 
 
As indicated by this formula, when the sensitivity is arbitrarily set at >90%, and the 
corresponding specificity is derived from the ROC curves (Figure 1), F varies only 
with the prevalence of iron deficiency. 
 
In summary, by screening with a cut-point for the diagnostic test result that is 
preselected to yield a high sensitivity (e.g. > 90% or > 95%), one can determine a 
prevalence range in which the negative predictive value that is within an acceptably 
high range (e.g. > 90% or > 95%) and that produces a variable fraction of persons in 
whom iron deficiency can be ruled out (Figure 2).  
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TABLE 1. Characteristics of the study population 
 
 All children Children without 
inflammation or 
Plasmodium infection 
n  338  84 
Age     
12-23.99 months 53.6% (181) 54.8% (46) 
24-36 months 46.4% (157) 45.2% (38) 
Sex, male 55.0% (186) 47.6% (40) 
Height-for-age z-score, SD -1.33 (1.4) -0.91 (1.5) 
Stunted (height-for-age z-score < -2 SD) 30.2% (102) 14.3% (12) 
Weight-for-height z-score, SD -0.14 (1.0) -0.15 (0.97) 
Wasted (weight-for-age z-score <-2 SD) 3.0% (10) 2.4% (2) 
Whole blood ZPP, μmol/mol haem 181 [124-282] 131 [98-239] 
Whole blood ZPP > 70 μmol/mol haem 97.9% (331) 97.6% (82) 
Erythrocyte ZPP, μmol/mol haem 142 [86-246] 117 [69-215] 
Erythrocyte ZPP > 70 μmol/mol haem 83.1% (281) 72.6% (61) 
Erythrocyte ZPP > 40 μmol/mol haem 96.7% (327) 95.2% (80) 
Haemoglobin concentration, g/L 105.0 (13.2) 111.7 (10.0) 
Anaemia (haemoglobin concentration < 110 g/L) 62.1% (210) 42.9% (36) 
Plasma ferritin concentration, μg/L 35.3 [17.1-67.2] a 17.3 [10.3-28.8] 
b 
Iron status c     
Deficient 17.1% (57/333) 32.1% (27/81) 
Replete 23.1% (77/333) 64.3% (54/81) 
Uncertain 59.8% (199/333) Not applicable  
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Plasma sTfR concentration, mg/L 2.43 [1.84-3.30] 2.11 [1.50-2.94] 
Plasma albumin concentration, g/L 34.8 (3.9) 37.4 (2.2) 
Plasma vitamin B12 concentration, pmol/L 400 [307-559] d 356 [283-452] e 
Plasma vitamin B12 concentration < 150 pmol/L 1.2% (4/332) 1.2% (1/80) 
Plasma CRP concentration, mg/L 2.9 [0.8-9.2] Not applicable  
Plasma AGP concentration, g/L 1.16 [0.9-1.55] Not applicable  
Inflammation     
Plasma CRP concentration > 5 mg/L 37.9% (128) Not applicable  
Plasma AGP concentration > 1.0 g/L 63.6% (215) Not applicable  
Plasma CRP concentration > 5 mg/L, or plasma AGP concentration > 1.0 
g/L 
66.9% (226) Not applicable  
Plasmodium infection     
P. falciparum 36.1% (122) Not applicable  
Plasmodium spp. other than P. falciparum 0.3% (1) Not applicable  
Missing 0.9% (3) Not applicable  
Values indicate mean (SD), median [25th and 75th percentile] or % (n) 
AGP: α1-acid glycoprotein; CRP: C-reactive protein; sTfR: soluble transferrin receptor; ZPP: zinc protoporphyrin 
 
Missing values, due to insufficient plasma volumes for analysis, resulted in a n=333, b n=81; c Deficient: plasma ferritin 
concentration < 12 μg/L, regardless of the presence or absence of inflammation; replete: plasma ferritin concentration ≥ 12 μg/L, 
in the absence of inflammation; uncertain: plasma ferritin concentration ≥ 12 μg/L, in the presence of inflammation defined as 
plasma concentrations of CRP > 5 mg/L or AGP > 1.0 g/L. Missing values, due to insufficient plasma volumes for analysis, 
resulted in d n=332 and e n=80. 
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TABLE 2. Factors associated with ZPP-haem ratio measured in whole blood or erythrocytes, crude analysis a 
 
Factor n Whole blood ZPP-haem ratio Erythrocyte ZPP-haem ratio 
Geometric 
mean 
Δ b (95% CI) Geometric 
mean 
Δ b (95% CI) 
Age         
12-23.99 months 162 199 Ref  163 Ref  
24-36 months 176 178 -
10.8% 
(-21.2% to 0.9%) 134 -18.1% (-4.3% to -29.9%) 
Sex        
Girls 152 179 Ref  135 Ref  
Boys 186 195 9.4% (-3.4% to 23.8%) 158 16.4% (-0.5% to 36.1%) 
Inflammation (CRP concentration > 5 mg/L)        
No 210 180 Ref  144 Ref  
Yes 128 201 11.4% (-1.9% to 26.5%) 153 6.6% (-9.3% to 25.4%) 
Inflammation (AGP concentration > 1 g/L)        
No 123 166 Ref  136 Ref  
Yes 215 201 21.4% (7.0% to 37.9%) 154 13.3% (-3.7% to 33.3%) 
Inflammation (CRP concentration > 5 mg/L or AGP 
concentration > 1 g/L) 
       
No 112 166 Ref  137 Ref  
Yes 226 199 20.0% (5.4% to 36.7%) 153 11.4% (-5.6% to 31.6%) 
Iron deficiency (ferritin concentration < 12 μg/L)        
No 276 173 Ref  132 Ref  
Yes 57 278 60.4% (36.9% to 87.8%) 255 93.6% (58.8% to 136.0%) 
Anaemia        
No 128 129 Ref  98 Ref  
Yes 210 236 82.3% (63.3% to 103.5%) 189 92.0% (65.9% to 122.1%) 
Plasmodium infection, any species        
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No 212 167 Ref  131 Ref  
Yes 123 230 37.5% (21.5% to 55.6%) 180 38.1% (18.6% to 60.8%) 
Plasma ferritin concentration, 5.11-fold change d, e   -
16.7% 
(-24.6% to -7.9%)  -18.1% (-24.1% to -11.6%) 
Plasma sTfR concentration, 1.43-fold change d   38.3% (34.0% to 42.7.0%)  66.8% (57.7% to 76.4%) 
Plasma CRP concentration, 2.72-fold change d   3.5% (0.8% to 6.2%)  6.8% (-1.2% to 15.5%) 
Plasma AGP concentration, 1.60-fold change d   23.7% (10.0% to 39.1%)  7.1% (-1.0% to 15.8%) 
Haemoglobin concentration, change by 13.2g/L f, g   -
29.8% 
(-33.1% to -26.2%)  -31.5% (-35.9% to -26.7%) 
Plasma albumin concentration, change by 3.9g/L f   -7.0% (-12.5% to -1.1%)  -1.4% (-8.9% to 6.7%) 
Plasma vitamin B12 concentration, change by 
213pmol/L f 
  7.0% (0.6% to 13.9%)  6.1% (-2.0% to 14.8%) 
 
AGP: α1-acid glycoprotein; CRP: C-reactive protein; GSD: geometric standard deviation; Ref: reference; SD: standard deviation; sTfR: soluble 
transferrin receptor; ZPP: zinc protoporphyrin 
a ZPP values were normalised by log-transformation; exponentiation of results yielded associations being expressed as relative differences; b 
Difference; c Based on HRP2- and pLDH-based dipstick test results; d Corresponding to 1 geometric standard deviation; e For example, a 5.11-fold 
increase in plasma ferritin concentration, which corresponds to a variation that is equivalent to addition of 1 SD on a log-transformed scale, is 
associated with a reduction in the whole blood ZPP-haem ratio by 16.7%; f Corresponding to 1 SD; g For example, an increase in haemoglobin 
concentration by 13.2g/L, which corresponds to an increase by 1 SD, is associated with a reduction in the whole blood ZPP-haem ratio by 29.8%. 
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TABLE 3. Factors associated with ZPP-haem ratio measured in whole blood or erythrocytes, multiple linear regression analysis a 
 
 Whole blood ZPP-haem 
ratio (model 1) 
Whole blood ZPP-haem 
ratio (model 2) 
Erythrocyte ZPP-haem 
ratio 
 Δ b (95% CI) Δ b (95% CI) Δ b (95% CI) 
Plasma ferritin concentration, 5.11-fold change 
c 
-10.1% (-14.3% to -5.6%) -9.6% (-14.0% to -4.9%) -
15.5% 
(-21.1% to -9.5%) 
Plasma sTfR concentration, 1.43-fold change c 34.8% (28.3% to 41.7%) 34.9% (28.3% to 41.8%) 45.3% (35.7% to 55.6%) 
Plasma CRP concentration, 2.72-fold change c 5.0% (0.1% to 10.0%) 5.4% (0.4% to 10.5%) 9.8% (2.8% to 17.2%) 
Haemoglobin concentration, change by 
13.2g/L d 
-13.9% (-18.3% to -9.4%) -
14.9% 
(-19.4% to -10.1%) -
14.5% 
(-20.7% to -7.9%) 
Plasmodium infection, any species e 17.3% (7.8% to 27.7%) 16.8% (7.4% to 27.2%) 93.3% (23.8% to 202.0%) 
Plasma albumin concentration, change by 
3.9g/L d 
― (eliminated) 3.0% (-1.7% to 8.0%) 2.2% (0.5% to 4.0%) 
 
CRP: C-reactive protein; sTfR: soluble transferrin receptor; ZPP: zinc protoporphyrin 
a ZPP values were normalised by log-transformation; exponentiation of results yielded associations being expressed as relative 
differences. Plasma concentrations of α1-acid glycoprotein (log-transformed), vitamin B12 (log-transformed), sex (binary) and age 
class (binary) were eliminated from all models through a manual stepwise backward elimination process with an removal 
criterion of p>0.05; b Difference; c Corresponding to 1 geometric standard deviation; d Corresponding to 1 SD; e Based on HRP2- and 
pLDH-based dipstick test results 
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TABLE 4. Diagnostic performance of zinc protoporphyrin-haem ratio, with 
dichotomised test results, to detect iron deficiency 
 
Whole blood ZPP > 70 μmol/mol 
haem 
n/n Estimate (CI) 
Sensitivity 27/27 100.0% (84.4%–100.0%) a 
Specificity 2/54 3.7% (0.9%–14.4%) a 
Positive predictive value 27/79 34.2% (23.5%–46.7%) a 
Negative predictive value 2/2 100.0% (28.6%–100.0%) a 
Prevalence 79/81 97.5% (91.4%–99.3%) b 
Erythrocyte ZPP > 40 μmol/mol 
haem 
   
Sensitivity 27/27 100.0% (84.4%–100.0%) a 
Specificity 4/50 7.4% (2.6%–19.5%) a 
Positive predictive value 27/77 35.1% (24.2%–47.8%) a 
Negative predictive value 4/4 100.0% (44.4%–100.0%) a 
Prevalence 77/81 95.1% (88.0%–98.1%) b 
a 97.5% CI; b 95% CI 
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FIGURE LEGENDS 
 
FIGURE 1. Ability of zinc protoporphyrin-haem ratio, either alone or in 
combination with haemoglobin concentration, to discriminate between children 
with and without iron deficiency 
 
Panel A: Receiver operating characteristics (ROC) curves for various blood markers, 
used alone, to discriminate between iron-deficient and iron-replete children. 
 
Panel B: As in Panel A, with haemoglobin concentration and whole blood ZPP, alone 
and in combination. 
 
Panel C: As in Panel A, with haemoglobin concentration and erythrocyte ZPP, alone 
and in combination. 
 
Panel D: As in Panel A, with combined haemoglobin concentration and whole blood 
ZPP, versus combined haemoglobin concentration and erythrocyte ZPP. 
 
Hb: haemoglobin concentration. Grey diagonal lines in ROC curves indicate a 
‘worst’ possible test, which has no discriminatory value and an area-under-the-curve 
(AUC) of 0.5. An ideal marker would have a curve that runs from the lower-left via 
the upper-left to the upper-right corner, yielding an AUC of 1.0. 
 
 
FIGURE 2. Application of a diagnostic strategy to rule out iron deficiency 
 
[Hb]: haemoglobin concentration, expressed in g/L; [whole blood ZPP]: whole blood 
ZPP content, expressed in μmol/mol haem. 
 
The diagnostic strategy in a screen-and-treat survey is based on two criteria: a) the 
probability of correctly diagnosing iron deficiency should exceed 90%; and b) iron 
deficiency can be ruled out if the probability of a negative test result being correct 
(negative predictive value) exceeds 90%. 
 
To meet the first requirement, a cut-off point for each diagnostic test result (top) is 
selected to yield a sensitivity of 90%; the corresponding specificity value is obtained 
from the ROC curves (Figure 1). For haemoglobin concentration and whole blood 
ZPP, the cut-off points were 122 g/L and 99 μmol/mol haem; the corresponding 
specificity values were 14.8% and 36.0%, respectively. When these markers were 
combined in a single diagnostic rule, 0.038689 [Hb] + 0.00694 [whole blood ZPP] > 
5.93120 had a specificity of 53.7%. 
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The negative predictive value (top panels, blue lines) depends on sensitivity and 
specificity values thus fixed, and the prevalence of iron deficiency. The second 
diagnostic criterion, i.e. the negative predictive value should exceed 90%, applies 
only within a limited prevalence range (top panels, red rectangle); at prevalence 
values exceeding this range, the negative predictive value will be below 90% and 
iron deficiency cannot be ruled out with diagnostic test applied (top). 
 
The percentage of children with a negative test result declines linearly with the 
prevalence of iron deficiency (middle panels, blue lines). The percentage of children 
for whom iron deficiency can be ruled out (middle panels, Y-intercepts of red 
rectangles) depends on the prevalence range in which the negative predictive value 
exceeds 90% (top panels, red rectangles). 
 
With fixed sensitivity and specificity values, the positive predictive value (bottom 
panels, blue lines) increase monotonically with the prevalence of iron deficiency. 
Within the prevalence range in which the negative predictive value exceeds 90% (top 
panels, red rectangles), the highest positive predictive value is 54% (for combined 
use of haemoglobin concentration and whole blood ZPP), indicating that additional 
tests (i.e. other than haemoglobin concentration and whole blood ZPP) are required 
to accurately determine iron status. 
 
For example, haemoglobin concentration > 122 g/L (left panels) has 90% sensitivity of 
detecting iron deficiency; at a true prevalence of iron deficiency < 14.1%, a negative 
test result obtained with this decision rules out iron deficiency with a probability of 
90% (upper left panel, red rectangle). Depending on the true prevalence of iron 
deficiency, such a cut-off for haemoglobin concentration would result in iron 
deficiency being ruled out in 14.1%-14.8% of children who are tested (middle left 
panel, red rectangle). Similarly, within a prevalence range < 28.6%, whole blood ZPP 
> 99 μmol/mol haem rules out iron deficiency in 28.6%-36% of children tested. 
Within a prevalence range of < 37.4%, 0.038689 [Hb] + 0.00694 [whole blood ZPP] > 
5.93120 rules out iron deficiency in 37.4%-53.7% of children. 
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Marker AUC (95% CI) P a
Haemoglobin concentration 62.7% (48.7%–76.6%) ‒
Whole blood ZPP 79.1% (68.2%–90.1%) 0.001
Erythrocyte ZPP 81.2% (71.6%–90.8%) <0.001
Haemoglobin concentration + whole blood ZPP 84.0% (74.7%–93.2%) 0.003
Haemoglobin concentration + erythrocyte ZPP 84.2% (75.7%–92.8%) 0.001
a Relative to haemoglobin concentration alone
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Chapter 6: Discussion and implications 
 
The WHO recommendation to use home fortification with multiple micronutrient 
powders containing 12.5 mg iron as ferrous fumarate for children aged 6-23 months 
[1] has been shown to reduce iron deficiency in children, but it has also raised public 
health concerns even when such fortification in malaria-endemic areas is 
accompanied by malaria control measures. Evidence from clinical trials has shown 
that administration of the high dose of 12.5 mg iron as ferrous salts increased the 
risks of morbidity and hospital admission among infants and young children [2-5]. 
These concerns created the motivation for our study and we proposed that 
providing a low dose of iron (3 mg as NaFeEDTA) may be safer and more tolerable 
because it is stable, with less oxidative stress, more tolerable, and is highly 
absorbable in high phytate diets resulting to fewer risks of morbidity and a likely 
improved adherence [6-7].  
 
Thus, we set out to compare 3mg iron as NaFeEDTA (investigational treatment) with 
12.5 mg iron as encapsulated ferrous fumarate (active control), with haemoglobin 
concentration response as the primary outcome. The study was conducted among 
12-36 month old children living in a malaria endemic area of western Kenya from 
January to December 2014. This being a non-inferiority study, we included a third 
arm (placebo) to adhere to regulatory guidelines for non-inferiority trials [8,9]. 
However, inclusion of a placebo in a non-inferiority trial is controversial. In our 
study we considered it ethical in the presence of the active control for various 
reasons: 1) in our study area, there is no national policy for preventive, community-
based supplementation or home fortification with iron in children under five years 
who are at a greater risk of iron deficiency anaemia; 2) our trial represents the only 
chance for eligible children to receive micronutrients powders with iron (for the iron 
arms) and micronutrients powders (for the placebo arm); 3) proof of efficacy for the 
iron treatments can be done through the use of the placebo arm, because failure for 
an investigational treatment to demonstrate effectiveness does not necessarily mean 
it is not efficacious, thus precluding any chance of making erroneous conclusions; 
and 4) it has also been argued that as medical knowledge increases, the use of a 
placebo in trials should decline. Conversely, increased medical knowledge has 
subsequently propelled the production of new treatments. Dropping the use of a 
placebo in a trial where a new treatment is being investigated limits the 
determination of efficacy and safety of the new treatment [10] consequently denying 
physicians opportunities to apply better treatment options when needed.  
 
The results of this study showed no evidence that daily home fortification for 30-
days with either a daily dose of 3 mg iron as NaFeEDTA or 12.5 mg iron as 
encapsulated ferrous fumarate were efficacious even after adjusting the treatment 
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effect for study design relative to placebo in both per protocol and intention to treat 
analysis. Also, in the sub-group analysis we found no change of intervention effects 
after adjusting for baseline factors that are prognostic for haemoglobin 
concentration. Following our failure to demonstrate efficacy, no further analysis was 
required to show non-inferiority. Though disappointing, these research results are 
informative and timely and are consistent with other subsequent studies that have 
shown lack of iron intervention effect on haemoglobin concentration. Such studies 
include three of the six trials in a meta-analysis that formed the basis for the WHO 
recommendation for daily home fortification with 12.5 mg iron as ferrous salts [11]. 
Nonetheless, our lack of efficacy for the iron treatments may elicit several queries 
regarding the study design, adherence to treatment, dosage, regimen and 
formulation, duration of intervention and other population-level factors such as 
chronic infections, inflammation status and consumption of inhibitory iron 
absorption compounds in food vehicles.  
 
Adherence to the two iron interventions as measured by the medication events 
monitoring system (the reference standard) showed that only 60.6% of the children 
consumed ≥ 24 sachets after 30 days of intervention meaning that there was a 
substantial proportion (~40%) of children that did not adhere to daily home 
fortification with micronutrient powders . Our evidence show that home-
fortification with 3 mg iron as NaFeEDTA failed to show efficacy as measured by 
comparison with placebo, but there are known benefits for administering 
fortification with 3mg iron as NaFeEDTA (outlined above). In addition, children 
with iron deficiency and anaemia have been shown to benefit more from iron 
fortification with NaFeEDTA when compared to placebo or fortification with 
electrolytic iron in high phytate diets [12]. We similarly recorded a reduction of iron 
deficiency in the absence of inflammation, this effect being absent in the group that 
received 12.5 mg iron as encapsulated ferrous fumarate. For safety reasons, we 
maintained the daily dose of NaFeEDTA within the Acceptable Daily Intake (ADI) 
for EDTA (0-1.9 mg kg-1 day-1) even though our study children consumed 
complementary food with high contents of phytate and phenolic compounds 
throughout the study period. Moreover, our data show that we could not increase 
the daily NaFeEDTA dose without a substantial proportion of children exceeding 
the ADI for EDTA. Accordingly, our findings are not unusual because they are 
consistent with other studies that show no effect on haemoglobin concentration 
where low iron with EDTA was consumed with diets containing high phytate 
compounds [4]. Thus researchers and technical experts may find these results useful 
in supporting a proposal to evaluate the amount of iron with EDTA when 
administered with high phytate diets [13]. Technical experts may also consider 
advocating the use of exogenous phytase (produced by Aspergillus niger) that has 
been shown to substantially increase iron absorption when consumed just before 
consumption of high phytate diet in primary school children [14].  
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On the other hand, the reference treatment, 12.5mg iron as ferrous fumarate not only 
failed to show efficacy in this present study, but it is associated with increased risks 
of morbidity and hospitalisation after administration to infants and young children 
(risks discussed above). These results elicit concerns as to whether 12.5mg iron as 
ferrous fumarate should remain an option for iron in home-fortification powders as 
recommended by the World Health Organisation, or whether other efficacious iron 
alternatives should be further sought.  
 
The intervention duration of 30 days was within the time period during which 
piperaquine, the long-acting anti-malarial drug administered at the start of iron 
treatment, was expected to protect against malaria. Nonetheless, at the end of the 30-
day intervention period, a substantial proportion of children carried Plasmodium 
parasites. This can be explained by: a) some children may not have completed the 
full therapeutic regimen, particularly the second and third doses that were to be 
administered unsupervised at home, prompting the need for direct observation of 
anti-malarial dose intake in children in future studies; b) an over-estimation due to 
persistence of P. falciparum HRP2 protein in circulation for several weeks after 
parasite clearance. It may be necessary to advocate for an increased duration after 
treatment of plasmodium infections to allow for reduction of HRP2 protein in 
circulation ; c) we used the manufacturer’s dihydroartemisinin-piperaquine dosage 
regimen that was recently shown to offer sub-optimal performance in children 
younger than five years. After we started our study, WHO revised the therapeutic 
dosage regimen [15]; the new recommendation is likely to yield a longer protective 
phase when dihydroartemisinin-piperaquine is administered for chemoprevention 
in future studies. Again, our 30 days duration may have been adequate for iron 
fortification because earlier trials conducted in Kenya among infants and young 
children supplemented with iron as ferrous fumarate improved haemoglobin 
concentration within 4 weeks [16]. Trials conducted in malaria-endemic areas with 
the same iron formulations but for a longer duration (6-18 months) showed no effect 
on haemoglobin concentration [4,5], meaning that there may be other factors that 
caused lack of efficacy for the iron interventions. 
 
The prevalence of inflammation was high in both iron groups. There was no 
evidence that inflammation at baseline influenced the effect of iron treatment on 
haemoglobin concentration. This study supports findings from a recent study 
conducted in Kenya that showed lower doses of iron with EDTA (2.5 mg iron as 
NaFeEDTA) and a high dose of 12.5 mg iron as ferrous fumarate increased the 
pathogenic profile and gut inflammation in infants and young children, even though 
no serious adverse events were reported [4]. The cut-off points for inflammation 
markers used in our study have been used in previous studies but they have not 
been validated in children. Thus it is possible that there was substantial blockage of 
iron absorption by elevated hepcidin concentration at lower inflammatory markers 
due to chronic infections caused by either viruses or low bacterial and parasitic 
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loads. Although our study children underwent a thorough medical examination 
prior randomization, we cannot rule out that there were still a substantial proportion 
of children with chronic infections and enteric inflammation. This, together with 
consumption of high amounts of iron-inhibiting factors in the food vehicles used for 
home fortification, and suboptimal adherence to daily home-fortification with iron 
may explain the lack of efficacy in both iron interventions.  
 
In our meta-analysis, we found a high level of heterogeneity in effects on 
haemoglobin concentrations across 15 trials, which may reflect methodological 
differences in iron dosage, formulation, duration of intervention, adherence, study 
quality, but, even more interestingly, may be due to population-level factors that 
determine efficacy (e.g. differences in prevalence of iron deficiency, chronic 
infections, inflammation status and inhibitory iron absorption compounds in food 
vehicles). Decisions made by policy makers regarding iron interventions mostly rely 
on results from meta-analyses; yet, information from our meta-analysis showed that 
the effect of iron treatment on haemoglobin concentration was highly heterogeneous 
and the pooled random-effect obtained may not reflect the actual effect due to 
differences in study methodology and populations. The finding from our updated 
meta-analysis showing a pooled effect of home fortification with iron-containing 
powders on haemoglobin concentration by 3.9g/L suggests a benefit in haemoglobin 
concentration across different settings, but does not allow prediction of efficacy in 
specific settings.  
 
The efficacy of home fortification with iron-containing micronutrient powders varies 
between trials, perhaps in part due to population differences in adherence. However, 
concerns have been raised regarding the most common methods of assessing 
adherence to home-fortifications with micronutrient powders, namely self-reporting 
or empty sachet counts. It has been argued that these tools either over-estimate or 
under-estimate adherence measurements of intervention treatments [16, 17]. Thus 
we set out to determine their accuracy and compare to the MEMS electronic device 
(which we nominated as the gold standard). Our results confirmed that both self-
reporting and sachet counts lead to over-estimates of adherence and may lead to 
biased conclusions. It also denies the investigator a chance to ascertain whether the 
correct regimen was followed. Adherence to iron supplementation has been 
associated with improved anaemia cure rates [19] but in our study there was no 
evidence of an association between haemoglobin response and adherence as 
measured either by self-reporting or sachet count. This may be due to over-reporting 
when in reality there was no consumption of micronutrient powders as scheduled. 
The strong association between MEMS caps opening and increase in haemoglobin 
concentrations supports findings of another trial that showed MEMS caps opening 
data positively reflected actual adherence and a positive effect to hypertensive 
treatment among the African-Americans [20]. We used beta-regression analysis to 
model adherence expressed as a fractional response of adherence to daily home-
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fortification because linear regression analysis of the untransformed fractional 
response although commonly used has several limitations ( for example; the effect of 
explanatory variables tend to be non-linear , proportions are not normally 
distributed and the variance is not constant but varies with the outcome). Our results 
showed that age of the parent or guardian was the only baseline factor that 
influenced adherence measures using MEMS device but we found no evidence that 
adherence was affected by other baseline characteristics of the parent or guardian 
(gender, education level) or child’s characteristics (sex, age, being infected by P. 
falciparum, wasting, stunting, sickness during intervention period). It has been 
shown elsewhere that older patients tend to adhere better to anti-retroviral treatment 
compared to their younger counterparts. Presumably older parents or guardians are 
better carers and attempt to observe medication instructions better. Hence, future 
studies assessing adherence to home-fortification of micronutrient powders in young 
children should consider using the MEMS device either alone or alongside self-
reporting and sachet counts to ensure accuracy of measurement and to complement 
adherence data respectively.  
 
Finally, in a recent trial, both whole blood ZPP and erythrocyte ZPP were shown to 
have little  diagnostic utility as a screening marker to manage iron deficiency in 
pregnant women, whether used as single tests or combined with haemoglobin 
concentration [21]. But in this present study, whole blood ZPP and erythrocyte ZPP 
in the absence of inflammation added diagnostic value in detecting iron deficiency 
compared to haemoglobin concentration alone in young children. Also, a single 
diagnostic score based on haemoglobin concentration and whole blood ZPP ruled 
out iron deficiency in a substantial proportion of children screened. However, we 
found it difficult to detect iron deficiency in the presence of inflammation. The 
increase in whole blood ZPP that was associated with Plasmodium infection and 
between ZPP and plasma C-reactive protein, can be explained partly due to the 
formation of bilirubin and other haemoglobin breakdown products in plasma that 
result from haemolysis and that fluoresce in the same wavelength range as 
protoporphyrins, also because plasma ferritin concentration can be elevated in the 
presence of infection-induced inflammation independently of iron status.  
Plasmodium infection was also associated with an even larger increase in erythrocyte 
ZPP, independently of inflammation, this result was unexpected because 
erythrocytes lack plasma constituents, which are removed by washing. Therefore, a  
possible explanation is that haemolysis-induced increase in erythropoietic activity 
under influence of Plasmodium infection that drives up the demand for iron in the 
erythron. The information presented here is extremely useful to technical experts 
and researchers and can be applied in a screen-and-treat approach. Specifically, a 
combination of haemoglobin concentration and whole blood ZPP in a single 
diagnostic score can be used as a rapid and convenient testing method to rule out 
iron deficiency in young children screened.  
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Study limitations 
Due to lack of funds we were unable to conduct biochemical analysis for urine and 
stool samples needed for assessment of hepcidin concentration and intestinal biota 
profile respectively. For the same reason, analysis of serum NTBI concentrations at 3 
hours after ingesting the first dose of iron fortificant and faecal calprotectin 
concentration at the end of the fortification period was not conducted. Assessments 
of urine hepcidin concentration would have provided us with substantial evidence 
for or against our arguments regarding iron blockage caused by increased hepcidin 
concentration at low levels of inflammation. Our study Objective 4 required us to 
analyse stool samples in order to compare effects of the two iron interventions on 
intestinal biota. Assessment of intestinal biota would have informed us which of the 
two iron interventions adversely increased the profile of pathogens and 
subsequently would increase gut inflammation.  
 
Recommendations for further research 
 
This was an explanatory type of study, therefore opportunities for future studies 
were deemed necessary to further elaborate, refine or validate our results.  
 
1. We conducted our study within 30 days in view of maintaining our daily iron 
administration within the estimated duration of the protective phase of 
antimalarial drugs. To rule out limited duration of intervention as an 
underlying factor for lack of efficacy for the iron intervention, a similar study 
design (non-inferiority) may be considered with a longer duration, perhaps 6 
or 12 months.  
 
2. Our data shows that the fortification dose of 3 mg iron as NaFeEDTA cannot 
be increased without a substantial proportion of children in the age range 
studied exceeding the ADI for EDTA (0-1.9 mg kg-1 day-1). It has been argued, 
however, that this acceptable daily intake may have been set too low, but 
more information is needed regarding the safe levels of EDTA for children 
when the amount of NaFeEDTA is increased for areas with high consumption 
of diets containing high phytate and phenolic compounds living in malaria 
endemic areas.  
 
3. In our study we defined inflammation as plasma C-reactive protein 
concentration >5 mg/L or plasma α1-acid glycoprotein concentration >1.0 g/L. 
These cut-off points, although used in many trials to determine inflammation 
status have not been validated in young children. Yet, there is a possibility 
that during chronic infections production of hepcidin increases in response to 
inflammatory cytokines and a substantial proportion of iron absorption can 
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be blocked at lower levels of inflammatory markers (plasma C-reactive 
protein concentration <5 mg/L or plasma α1-acid glycoprotein concentration 
<1.0 g/L).  
 
4. Evidence in our trial may be insufficient to recommend home fortification in 
all settings, but the high heterogeneity observed in the meta-analysis should 
stimulate subgroup analysis or meta-regression to identify population-
specific factors that determine efficacy.  
 
5. The association between age of the parent or guardian and adherence to home 
fortification was the result of exploratory analyses. In order to identify and 
understand the determinants of adherence to home fortification of 
micronutrient powders there is need to specifically design a trial that will use 
latent class analysis which may be helpful in defining subgroups that are 
prognostic to home-fortification adherence.  
  
 
6. Point-of-care tests are rapidly developing, with quantitative tests already 
being commercially available for plasma concentrations of ferritin and C-
reactive protein, and for various infections. Therefore, further research is 
required to extend and validate our diagnostic utility of ZPP approach with 
appropriately selected reference standard for iron deficiency in a population 
that include individuals with inflammation and infections.  
Way forward 
In our conceptual framework (chapter 1), we anticipated a substantial increase in 
haemoglobin concentration with co-administration of drug treatments and home-
fortification with the two iron formulations at a frequency and duration that may 
control anaemia. We administered the daily home fortification within a duration of 
30 days after providing a post treatment prophylactic phase by administering 
dihydroartemisinin-piperaquine, praziquantel and Albendazoles to the study 
children, 3 days’ prior randomization to the intervention groups. In this study, home 
fortification with 3mg iron as NaFeEDTA and 12.5mg iron as encapsulated ferrous 
fumarate had a mean (SD) haemoglobin concentration (g/L) of 110g/L (12.5g/L) and 
108.6g/L(12,0) respectively at the end of 30 days. Several factors, discussed above, 
may have led to this suboptimal increase of haemoglobin concentration (figure 1, 
panel 1). We selected a relatively short 30-day intervention with iron in the 
expectation that premedication with dihydroartemisinin-piperaquine will prevent 
malaria during this period, with a long-term view that the protection afforded by 
repeated chemoprevention with this combination drug would allow time windows 
for safe administration of short courses of iron intervention. In Burkina Faso pre-
school children, two cycles of chemoprevention with dihydroartemisinin-
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piperaquine, administered at the same target dose as in our study, resulted in a 
protection against malaria [22]. Thus if we maintain the duration of 30 days and 
increase the frequency of co-administering the anti-malarial treatment using the 
recent WHO revised therapeutic dosage regimen [15], closely monitor the uptake of 
2nd and 3rd dosage at the research clinic, and treat all children with common bacterial 
infections and any other enteric infections as determined by hepcidin concentrations 
alongside other inflammation markers, test and eliminate children with blood 
disorders, then we anticipate a substantial increase in the  haemoglobin 
concentration as demonstrated in figure 1 panel 2. 
 
Figure 1: Frequency and duration of co-administering drug treatments and daily 
home fortifications  
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Appendix 2: Informed consent form 
 
A study to assess the safety and efficacy of home fortification with iron 
in Kenyan children 
 
General 
1. I have attended a meeting where I was informed about the aims and procedures 
of this study. I also read the information sheet about this study, or someone has 
read the information sheet to me. I understand why the study is being done and 
what I have to do to participate. 
 
Signature/thumb print of parent/guardian:__________________________ 
 
Screening and enrolment 
2. I understand that I will be asked information about my child, and consent for my 
child to undergo medical examination and to donate samples of blood (by arm 
prick; 6 mL, a volume equal to one table spoon), urine and stool. 
3. I consent that my child will be administered medicines (albendazole, praziquantel 
against worms, and dihydroartemisinin-piperaquine against malaria).  
4. I understand that 3 days after screening, I am expected to bring my child back to 
the health facility where I will be given the outcome of the medical examination. 
Depending on the outcome of the medical examination my child may or may not 
be enrolled in the study. If my child successfully passes the screening process, I 
consent to continue with the randomization process. 
Signature/thumb print of parent/guardian:__________________________ 
 
Randomisation 
5. I understand that my child will be allocated by chance (‘randomly’) to one of 3 
groups, and that, depending on the group, my child will receive sachets containing 
either 12.5 mg iron as ferrous fumarate, or 3 mg iron as sodium iron EDTA, or no 
iron. 
6. I consent for the contents of the first sachet to be given at the research dispensary. 
7. I understand that my child is allowed to drink and eat food given by the research 
team in the period starting 2h before the first dose is given, and 3h afterwards. I 
agree to not give any other food to my child in this time period.  
8. I consent that, 3 hours after the first dose is given, another blood sample (about 5-
6 drops) will be collected by finger prick from my child. 
 
Signature/thumb print of parent/guardian:__________________________ 
 
Intervention 
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9. I understand that I will be given a dispensing bottle with 29 sachets, and that this 
bottle will remain property of the project. I agree to keep the dispensing bottle for 
the duration of the study in a safe place. 
10. I consent to each day add and mix the contents of a single sachet to a small amount 
of uji or other food, and to ensure that my child will consume all of this food. 
11. I understand and consent that community volunteers will visit my home at least 
once a week to answer questions that I may have about the study.  
12. I understand that, if my child becomes sick during the 30-day study period, I am 
expected to take my child for routine care to the regular health services. 
 
Signature/thumb print of parent/guardian: __________________________ 
 
At 30 days after start of intervention 
13. I consent for samples of blood (6 mL) by arm prick, stool and urine to be collected 
at 30 days after the start of the study.  
14. I understand that, at 30 days after the start of the study, the study team and I will 
be informed whether the sachets given to my child contained iron or not. 
15. I understand that, if my child received no iron, he or she again will be given 
antimalarial medicines (dihydroartemisinin-piperaquine) and 30-day supply of 
sachets with iron (12.5 mg iron as ferrous fumarate) in the dispensing bottle. 
16. I understand that, if my child received iron, field staff will collect the dispensing 
bottle with the electronic device 
 
Signature/thumb print of parent/guardian: __________________________ 
 
Follow-up after 30 days of intervention 
17. I understand that, if my child received no iron, he or she will leave the study at 30-
days after the intervention was stopped (thus 60 days after the start of the study), 
and that field staff will collect the dispensing bottle with the electronic device. 
18. I understand that, if my child received iron, he or she will continue to be followed 
for a maximum of 100 days, and that the end date will be decided by chance. I 
consent that, at the end date, two small blood samples (total: 5-6 drops) will be 
collected by finger prick. I understand that my child will then be given antimalarial 
medicines (dihydroartemisinin-piperaquine) and 30-day supply of sachets with 
iron (12.5 mg iron as ferrous fumarate). I understand that my child will then leave 
the study. 
19. I understand that, if my child becomes sick during the 30-day study period, I am 
expected to take my child for routine care to the regular health services. 
 
Signature/thumb print of parent/guardian: __________________________ 
 
Storage and future use of samples 
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20. I understand that samples of blood, stool and urine will be used for laboratory 
tests, and to check for hereditary factors that may affect malaria and anaemia. I 
consent to these samples being retained for unspecified use during or after the 
conclusion of the research project. 
21. I consent for small units of blood, stool and urine samples may be taken abroad for 
specialized analysis that cannot be easily done in Kenya. 
22. I understand that the results of these tests will remain confidential, regardless of 
whether the tests will be conducted within or outside Kenya.  
 
Signature/thumb print of parent/guardian: __________________________ 
 
Benefits and compensation 
23. I understand that I will be reimbursed for transport expenses made to take my 
child to the health facility for the purpose of the study. 
24. I understand that, when requested to stay at the health facility for more than 6 
hours for the purposes of the study, I will receive food (breakfast, lunch or snacks) 
free of charge. 
25. I understand that there will be no other compensation for participation in the 
study, whether financial or otherwise. 
 
Signature/thumb print of parent/guardian: __________________________ 
 
Voluntary participation and confidentiality 
26. I know that all my personal information will remain confidential. 
27. I know that I am doing this by choice, and that I do not have to take part in this 
study. I understand that I can withdraw at any moment from the study, without 
providing reasons and without affecting the care I am usually given at local health 
centres. 
28. I have asked all the questions that I wanted to ask, and they have all been 
answered. I know that I can ask any other questions as the study proceeds. 
 
I agree to take part in this study, and received a signed copy of this agreement. 
 
Date: __  __ / __  __  2014 
 
I am the father/mother/legal guardian of (name of the 
child):__________________________ 
 
Screening number: __________________________ 
 
Name of parent/guardian:__________________________ 
 
Signature/thumb print of parent/guardian:__________________________ 
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This form has been read by / I have read the above parent/guardian in a language that 
(s)he understands. I believe that (s)he has understood what I have explained and (s)he 
has made the free choice to participate in this study. 
 
Name of nurse/fieldworker: __________________________ 
 
Signature of nurse/fieldworker:__________________________ 
 
Name of witness: __________________________ 
 
Signature of witness:__________________________ 
 
Contacts: 
 
1. Emily Teshome, Trial Coordinator 
London School of Hygiene and Tropical Medicine, UK 
Mobile +254 786 401886; email: emily.teshome@lshtm.ac.uk 
 
2. Dr. Hans Verhoef, Principle Investigator 
London School of Hygiene and Tropical Medicine, UK/Wageningen University, 
The Netherlands 
Mobile +31 6 8325225, email: hans.verhoef@wur.nl 
 
3. Dr. Pauline Andang’o, Co-Investigator 
Maseno University, Kenya 
Mobile +254 728 485729; email: paulango@hotmail.com 
 
4. Professor A.N. Guantai  
KNH/UoN/-ERC 
College of Health Sciences 
P.O. Box 19676 code 00200 
Tel +254 20 2726300 Ext 44355 email: uonknh_erc@uonbi.ac.ke 
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Appendix 3: Participants information brochure 
 
A study to compare the efficacy and safety of different iron 
formulations in Kenyan children  
 
We would like to invite you to take part in a research study. Before you decide you need to 
understand why the research is being done and what it would involve for you. Please take 
time to read the following information carefully. Talk to others about the study if you wish. 
Ask us if there is anything that is not clear or if you would like more information. Take time 
to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
We want to conduct a study to compare home fortification with two iron formulations. Many 
young children in Kenya have anaemia, a disorder that is characterized by blood with a light 
red colour, instead of a healthy dark red. The red pigment in blood is necessary to transport 
oxygen from inspired air to muscle. Children with anaemia often feel weak or tired, and may 
have difficulty learning. To prevent anaemia in children, medical doctors often prescribe 
supplements that contain 12.5 mg iron in a specific form (ferrous salts). A new form of iron 
has recently become available that can probably be given at lower doses, because the body is 
better able to absorb this type of iron. 
 
In our study, we will divide young children into three groups and give each group a different 
treatment. Group 1 will receive the form of iron that has been used so far (12.5 mg iron as 
ferrous fumarate), Group 2 will receive the new form of iron (3 mg iron as sodium iron EDTA), 
and Group 3 will receive no iron. The results will be compared to determine if the new type 
of iron (3 mg iron as sodium iron EDTA) can prevent anaemia, and to determine if it is equally 
as good as the form of iron that has been used so far (12.5 mg iron as ferrous fumarate). 
 
We will provide both forms of iron in sachets (little bags). Each day, the mother should empty 
and mix the contents of a single sachet into ready-prepared uji or some other type of food, 
before giving it to the child. This should be repeated every day for a period of 30 days. The 
child will be followed for some time afterwards. 
 
Although iron is good to prevent anaemia, there are some concerns that it may increase the 
risk of malaria. For this reason, we will treat each child with a special medicine against malaria 
(dihydroartemisinin-piperaquine) at the start of the study, before the first dose of iron is 
provided. This medicine will protect the child against malaria for the time period in which the 
child will receive iron. In addition, all children will be dewormed at the start using two drugs 
(albendazole and praziquantel). 
 
Do you have to participate? 
We have asked you to take part because your child is within the age range suitable for our 
study. In total, we want to study 324 children. You can let your child join the study at your 
own free will, and withdraw your child at any moment, with or without giving reasons. If you 
decide not to participate, or to withdraw from the study, this will not affect the normal care 
you receive in clinics or hospital elsewhere.  
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Read this information sheet and listen to our explanation of the study. We will then ask you 
to sign a consent form to show you have agreed to take part. 
 
What will happen to you if you take part? 
 
Screening visit: Our staff will invite you and your child to our research clinic to tell you about 
the aims and procedures of the study. If you agree for your child to participate, we will ask 
you to sign their fingerprint on a consent form. To decide whether your child can participate 
in the study, we will then ask you questions about your child, we will carry out a medical 
examination, and we will then collect samples of blood (6 mL, a volume equal to one table 
spoon) by arm prick, urine and stool from the child. This will take at least several hours. We 
will ask you to stay until if the child has produced stool. If necessary, we will invite you and 
your child again the next day to try again. After sample collection, your child will be 
administered medicines (albendazole, praziquantel against worms, and dihydroartemisinin-
piperaquine against malaria). You will be asked to bring your child again to the research clinic 
3 days later. 
 
Randomisation visit: At this visit, we will use the information collected so far to decide if your 
child can take part in the rest of the study. Participating children will receive sachets with 
powder. These sachets will be contained in a special dispensing bottle that you will receive 
with instructions for use. For one-third of children, these sachets will contain 12.5 mg iron as 
ferrous fumarate, one-third will contain 3 mg iron as sodium iron EDTA, and one-third 
contains no iron. The allocation to group will be decided by chance (randomly). All sachets 
will look identical; we will not know which supplements contain iron until after the study. 
The first sachet will be given with food at the research dispensary. From 2h before this point 
until 3h afterwards, children will be allowed to drink but can only eat foods selected by the 
project team. We will then collect another blood sample (about 5-6 drops) by finger prick. 
From then on, community volunteers will daily supervise the supplementation in or close to 
your homestead. 
 
During the 30-day intervention period: In the next 30 days, you should add and mix the contents 
of a single sachet to uji or any other food given to the child. Community volunteers will visit 
your home at least once a week to answer questions that you may have about the study. 
Children who become sick during this 30-day period will be referred to receive routine care 
by the regular health services. You may decide to withdraw your child at any point from the 
study. You may refuse to give reasons for your refusal, or to give permission for future 
collection of samples. 
 
End-of-intervention survey: At the end of the 30-day period, we will collect the dispensing bottle 
and ask you some questions. We will again collect samples of blood (6 mL) by arm prick, stool 
and urine, using the same procedures as earlier. For each child, we will then break the 
randomisation code. Those who received placebo will be given antimalarial medicines 
(dihydroartemisinin-piperaquine) and 30-day supply of sachets with iron (12.5 mg iron as 
ferrous fumarate). 
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Follow-up after the 30-day intervention period: For children who received placebo, field staff will 
collect the dispensing bottle with the electronic device at the end of this 30-day period. 
Children who received iron will continue to be followed for a maximum of 90 days. In this 
period, we will collect a single sample of blood (5-6 drops, by finger prick). The time point for 
this collection will be decided by chance: for some children it may be as early as 1 week after 
home fortification was stopped; for others, it may be at the end of the 90-day period. Children 
who become sick during this follow-up period will be referred to receive routine care at the 
health facility. Immediately following blood collection, children will be withdrawn from 
further study and will receive antimalarial medicines (dihydroartemisinin-piperaquine) and 
30-day supply of sachets with iron (12.5 mg iron as ferrous fumarate). Field staff will also 
collect the dispensing bottle with the electronic device at this time. 
 
To summarise, we will collect four blood samples from each child: 
 Randomisation visit: 1 sample of 6 mL (a volume equal to one table spoon), to be collected 
by arm prick; 
 3 hours later: 1 sample of 5-6 drops, to be collected by finger prick; 
 At the end of the 30-day period: 1 sample of 6 mL, to be collected by arm prick; 
 After the 30-day intervention period: 1 sample of 5-6 drops, to be collected by finger prick. 
 
We will store part of the blood samples in frozen condition, so that we can 
subsequently conduct tests to assess the success of the interventions. We may also 
check for hereditary factors that affect malaria and anaemia. Some of these tests may 
have to be done abroad. 
 
Confidentiality: Results of this study will be shared with the public in a form of academic 
publication or presentation. The purpose of this publication or presentation is to create 
awareness and promote understanding of safely and efficiently treating anaemia in malaria 
endemic areas. 
 
We will keep any information about your child confidential. Readers of the publication based 
on this research will not know that you gave this information. All personal information will 
be stored securely. This means that whenever we write or talk about anything we have been 
told, we never use your real name. The only information that we may have to pass on is if 
your child is at risk of serious harm. 
 
Benefits and compensation: You will not receive financial benefits for participating in this study. 
If you need to stay more than 4 hours, we will give you a compensation gift to account for the 
lost hours. 
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Appendix 4: Self reporting form 
 
 
 
SEICK PROJECT 2014
Date of start To be filled by caregiver immediately after adminstering contents in the sachets
ID No of Child
Location
End of reporting date
Tick the time child consumes warm Uji o r any warm meal with Micronutrient powder
Day Morning
Mid-
Morning Lunch
Mid-
afternoo Night
Did not 
consume
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Self- Reporting Sheet 
Page 169 of 169 
 
Appendix 5: Follow-up checklist 
 
Follow-up visit form 
Sub-Location_________________ Village  Name _________________       ID No. of child_________      
Name of Caregiver_________________________________  Research Assistant _______________ ___________________ 
 
Week Date of Visit 
DD/MM/YY 
Study 
Child 
Present 
Yes/No 
Caregiver  
Present  
 
Yes/No 
If caregiver is not 
present who else 
was present? 
Indicate name 
and relation to 
child 
Problems /challenges raised by  Caregiver   Observe if the 
following are 
still in  good 
use. (Please do 
not open the 
MEMS device) 
Tick where 
present 
1     1. 
2. 
3. 
4. 
 
MEMS 
 
 
Self- reporting 
2     1. 
2. 
3. 
4. 
 
MEMS  
 
Self- reporting  
3     1. 
2. 
3. 
4. 
 
MEMS  
 
Self- reporting  
4     1. 
2. 
3. 
4. 
 
MEMS  
 
Self- reporting  
 
